HK1119700A

HK1119700A - Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors

Info

Publication number: HK1119700A
Application number: HK08112960.3A
Authority: HK
Inventors: Stanton Furst Mchardy; John Adams Lowe Iii
Original assignee: 辉瑞产品有限公司
Priority date: 2005-04-08
Filing date: 2006-03-27
Publication date: 2009-03-13

Description

Bicyclic [3.1.0] heteroaromatic amides as type I glycine transport inhibitors

Technical Field

The present invention relates to bicyclo [3.1.0] heteroaromatic amides and pharmaceutical compositions containing the same, and their use in the treatment of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other dysfunctions in mammals, including humans. These compounds show activity as glycine type I transporter inhibitors.

Background

Schizophrenia is a progressive neuropathy that manifests early in thought disorders such as hallucinations, paranoia, and abnormal thought patterns, which are collectively considered positive symptoms. These readily identifiable symptoms give the disease the following historical name: "mania (madness)". As the disease progresses, some negative symptoms such as social withdrawal and anhedonia, and cognitive symptoms such as dementia become more and more evident. Only about one third of schizophrenic patients are successfully cured and returned to society, while others are usually sent to specialized institutions. The burden on society and the cost of family members of patients with these devastating disorders make them one of the most costly of all CNS diseases.

Traditionally, pharmacotherapy of schizophrenia involves blocking the dopamine system, which is thought to cause its positive symptoms. But these treatments overlook the negative and cognitive aspects of the disease. Another neurotransmitter system that is thought to play a role in schizophrenia is the glutamate system, which is the major excitatory transmitter system in the brain. This assumption is based on the following observations: by blocking the glutamate system with compounds such as PCP ("angel powder"), many symptoms of schizophrenia, including their positive, negative and cognitive aspects, can be reproduced. If schizophrenia involves a deficit in glutamatergic transmission, it is beneficial to enhance the glutamate system, in particular the NMDA receptor. While glutamate is the primary agonist of NMDA receptors, glycine requires co-agonists to modulate the "degree of response" (tone) of the receptor to glutamate response. Increasing this "degree of response" by potentiating the action of glycine enhances NMDA neurotransmission and provides potential benefit in the treatment of schizophrenia.

A specific mechanism for enhancing the glycinergic "response" of NMDA receptors has recently been by Bergeron et al (Proc.Natl.Acad.Sci.USA，95, 15730, (1998)) which is incorporated herein by reference. This group found that specific and potent inhibitors of the glycine type 1 transporter (GlyT1) that remove glycine from synapses at NMDA receptors, termed NFPS (WO97/45115), could enhance NMDA receptor function. For example, NFPS increases the postsynaptic current driven by the NMDA receptor, an effect blocked by both a specific NMDA-site antagonist and a glycine-site antagonist. This work shows that even though glycine levels in the brain are higher than required for use as an NMDA receptor co-agonist, GlyT1 is still effective in removing glycine from the synapse, and that inhibition by GlyT1 enhances NMDA receptor function. The present invention provides GlyT1 inhibitors useful for the treatment of dysfunctions or disorders such as schizophrenia by enhancing glutamatergic neurotransmission.

Disclosure of Invention

The present invention relates to compounds of formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein

Formula I

Wherein R is₁Represents a heteroaryl group selected from: imidazolyl and thiazolesA heteroaryl group, wherein said heteroaryl group is optionally substituted with one or more substituents selected from the group consisting of: -OH, -NR₇R₈Halogen, (C)₁-C₈) Alkyl, (C)₃-C₁₀) Cycloalkyl group, (C)₁-C₈) Alkoxy group, (C)₁-C₁₂) Alkoxyalkyl group, (C)₁-C₈) Hydroxyalkyl radical, (C)₆-C₁₄) Aryl and benzyl;

R₂、R₃and A each independently represents H or (C)₁-C₈) Alkyl, wherein said alkyl is optionally substituted with one or more-OH, (C)₁-C₈) Alkoxy, -NR₇R₈Or halogen substitution;

q represents- (CH)₂)_n-, where n is 1, 2, 3 or 4, or- (CH)₂)_m-O, wherein m is 2, 3 or 4;

z represents (C)₆-C₁₄) Aryl group, (C)₁-C₈) Alkyl or (C)₃-C₈) A cycloalkyl group;

R₄and R₅Each independently represents H, halogen, (C)₁-C₈) Alkyl, (C)₆-C₁₄) Aryl group, (C)₆-C₁₄) Aryloxy group, (C)₁-C₈) Alkoxy, (3-to 10-membered) heterocycloalkyl or (C)₃-C₈) A cycloalkoxy group; wherein R is₄And R₅Optionally substituted by one or more-OH, (C)₁-C₈) Alkoxy, -NR₇R₈Or halogen substitution;

y represents-R₆、-(CH₂)_o-R₆、-C(R₆)₃or-CH (R)₆)₂Wherein o is 1, 2 or 3;

R₆represents H, (C)₆-C₁₄) Aryl group, (C)₁-C₁₀) Alkyl radical、(C₃-C₁₀) Cycloalkyl group, (C)₅-C₁₈) Bicycloalkyl, (C)₅-C₁₈) Tricycloalkyl, (3-10 membered) heterocycloalkyl, (5-10 membered) heteroaryl, -C (═ O) NR₇R₈OR-C (═ O) OR₇Wherein said R is₆Groups may be optionally substituted with one or more X groups;

wherein X is-OH, (C)₁-C₈) Alkoxy, -NR₁₁R₁₂、-SO₂R₁₀、-C(＝O)R₁₀Halogen, cyano, (C)₁-C₈) Alkyl, (C)₁-C₁₀) Alkoxyalkyl, (5-to 10-membered) heteroaryl, (C)₆-C₁₄) Aryl group, (C)₆-C₁₄) Aryloxy, benzyl or (C)₁-C₈) A hydroxyalkyl group;

wherein R is₇And R₈Independently represent H, (C)₁-C₈) Alkyl, (C)₃-C₈) Cycloalkyl, (5-to 10-membered) heterocycloalkyl, (C)₁-C₈) Hydroxyalkyl, (5-to 10-membered) heteroaryl or (C)₁-C₁₀) An alkoxyalkyl group; wherein R is₇And R₈Optionally substituted with one or more X groups;

or R₇And R₈Together with the nitrogen to which they are attached may form a (3-to 10-membered) heterocycloalkyl group optionally substituted with one or more X groups;

wherein R is₁₀Is represented by (C)₁-C₈) Alkyl, (C)₃-C₈) Cycloalkyl, (3-to 10-membered) heterocycloalkyl, (C)₁-C₈) Hydroxyalkyl, (5-to 10-membered) heteroaryl or (C)₁-C₁₀) An alkoxyalkyl group;

wherein R is₁₁And R₁₂Independently represent H, (C)₁-C₈) Alkyl, (C)₃-C₈) Cycloalkyl, (5-to 10-membered) heterocycloalkyl, (C)₁-C₈) Hydroxyalkyl, (5-to 10-membered) heteroaryl or (C)₁-C₁₀) An alkoxyalkyl group.

Detailed Description

The terms "halogen" and "halo" as used herein include, unless otherwise indicated, F, Cl, Br and I.

The term "alkyl" as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched moieties. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, cyclopropylmethylene (-CH)₂-cyclopropyl) and tert-butyl.

The term "alkenyl", as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon double bond, wherein alkyl is as defined above. Examples of alkenyl groups include, but are not limited to, ethenyl and propenyl.

The term "alkynyl", as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon triple bond, wherein alkyl is as defined above. Examples of alkynyl groups include, but are not limited to, ethynyl and 2-propynyl.

The term "alkoxy", as used herein, unless otherwise indicated, refers to "alkyl-O-", wherein "alkyl" is as defined above. Examples of "alkoxy" include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, pentoxy, and allyloxy.

The term "alkoxyalkyl", as used herein, unless otherwise indicated, refers to alkyl-O-alkyl-wherein alkyl is as defined above.

The term "hydroxyalkyl", as used herein, unless otherwise indicated, refers to-alkyl-OH, wherein alkyl is as defined above.

The term "alkenyloxy", as used herein, unless otherwise indicated, refers to "alkenyl-O-", wherein "alkenyl" is as defined above.

The term "alkynyloxy", as used herein, unless otherwise indicated, refers to "alkynyl-O-", wherein "alkynyl" is as defined above.

The term "cycloalkyl", as used herein, unless otherwise indicated, includes non-aromatic saturated cyclic alkyl moieties wherein alkyl is as defined above. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. "Bicycloalkyl" and "tricycloalkyl" include nonaromatic saturated cyclic alkyl moieties consisting of two or three rings, respectively, wherein the rings share at least one carbon atom. "Bicycloalkyl" and "tricycloalkyl" also include cyclic moieties consisting of two or three rings, respectively, wherein one ring is aryl or heteroaryl, and wherein the rings share two carbon atoms. For the purposes of the present invention, unless otherwise indicated, bicycloalkyl includes spiro and fused ring groups. Examples of bicycloalkyl groups include, but are not limited to, bicyclo- [3.1.0] -hexyl, bicyclo- [2.2.1] -hept-1-yl, norbornyl, spiro [4.5] decyl, spiro [4.4] nonyl, spiro [4.3] octyl, spiro [4.2] heptyl, indane, teralene (1, 2, 3, 4-tetrahydronaphthalene), and 6, 7, 8, 9-tetrahydro-5H-benzocycloheptene. An example of a tricycloalkyl group is an adamantyl group. Other cycloalkyl, bicycloalkyl and tricycloalkyl groups are well known in the art and these groups are included in the definitions of "cycloalkyl", "bicycloalkyl" and "tricycloalkyl" herein. "cycloalkenyl", "bicycloalkenyl" and "tricycloalkenyl" refer to the individual cycloalkyl, bicycloalkyl and tricycloalkyl moieties as defined above, which are non-aromatic, except that they each include one or more carbon-carbon double bonds ("in-ring" double bonds) connecting a carbon ring member and/or one or more carbon-carbon double bonds ("out-of-ring" double bonds) connecting a carbon ring member to an adjacent acyclic carbon atom. Examples of cycloalkenyl groups include, but are not limited to, cyclopentenyl, cyclobutenyl, and cyclohexenyl. One non-limiting example of a bicycloalkenyl group is a norbornenyl group. Cycloalkyl, cycloalkenyl, bicycloalkyl and bicycloalkenyl also include groups substituted with one or more oxo moieties. Examples of such groups bearing oxo moieties are oxocyclopentyl, oxocyclobutyl, oxocyclopentenyl and norcamphoryl (norcamphoryl). Other cycloalkenyls, bicycloalkenyls, and tricycloalkenyls are well known in the art and these groups are included in the definitions of "cycloalkenyl", "bicycloalkenyl", and "tricycloalkenyls" herein.

The term "aryl" as used herein includes, unless otherwise indicated, organic groups obtained by removing one hydrogen from an aromatic hydrocarbon, such as phenyl (Ph), naphthyl, indenyl, indanyl and fluorenyl. "aryl" includes fused ring groups in which at least one ring is aromatic.

The terms "heterocycle" and "heterocycloalkyl", as used herein, unless otherwise indicated, refer to a non-aromatic cyclic group containing one or more heteroatoms, preferably 1 to 4 heteroatoms, each selected from O, S and N. "heterobicycloalkyl" groups include non-aromatic bicyclic cyclic groups in which the rings share one or two atoms and in which at least one of the rings contains a heteroatom (O, S or N). "heterobicycloalkyl" also includes bicyclic cyclic groups in which one of the rings is aromatic or heteroaromatic, and in which the rings share one or two atoms, and in which at least one of the rings contains a heteroatom (O, S or N). Unless otherwise indicated, for purposes of the present invention, heterobicycloalkyl includes spiro and fused ring groups. In one embodiment, each ring in the heterobicycloalkyl group contains up to 4 heteroatoms (i.e., from 0 to 4 heteroatoms, so long as at least one ring contains at least one heteroatom). The heterocyclyl groups of the present invention may also include ring systems substituted with one or more oxo moieties. Examples of non-aromatic heterocyclic groups are aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, piperazinyl, 1, 2, 3, 6-tetrahydropyridinyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholino, thiomorpholino, thiaxalinyl, pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1, 3-dioxolanyl, pyrazolinyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo [3.1.0] hexyl, 3-azabicyclo [4.1.0] heptyl, quinolizinyl, quinuclidinyl, spirocyclo, 1, 4-dioxadecyl [4.5] decyl, 1, 4-dioxaspiro [4.4] nonyl, 1, 4-dioxaspiro [4.3] octyl, and 1, 4-dioxaspiro [4.2] heptyl.

As used herein, unless otherwise indicated, "heteroaryl" refers to an aromatic group containing one or more heteroatoms, preferably 1 to 4 heteroatoms, selected from O, S and N. Polycyclic groups containing one or more heteroatoms wherein at least one ring of the group is aromatic are "heteroaryl" groups. Heteroaryl groups of the present invention may also include ring systems substituted with one or more oxo moieties. Examples of heteroaryl groups are pyridyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolinyl, isoquinolinyl, 1, 2, 3, 4-tetrahydroquinolinyl (1, 2, 3, 4-tetrahydroquinolinyl), tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, indolyl, benzimidazolyl, benzofuryl, cinnolinyl, indazolyl, indolizinyl (indolizinyl), 2, 3-naphthyridinyl, triazinyl, 1, 2, 4-triazinyl (trizanyl), 1, 3, 5-triazinyl, isoindolyl, 1-oxoisoindolyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl (furazanyl), benzofurazanyl, benzothiophenyl, benzotriazole, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, thienyl, triazolyl, pyrazinyl, thiazolyl, isothiazolyl, thiazolyl, and the like, Naphthyridinyl (naphthyridinyl), dihydroquinolinyl, tetrahydroquinolinyl, dihydroisoquinolinyl, tetrahydroisoquinolinyl, benzofuranyl, furopyridinyl, pyrrolopyrimidinyl, and azaindolyl.

The term "cycloalkoxy", as used herein, unless otherwise indicated, refers to "cycloalkyl-O-", wherein "cycloalkyl" is as defined above.

The term "aryloxy", as used herein, unless otherwise indicated, refers to "aryl-O-", wherein "aryl" is as defined above.

The term "heterocycloalkoxy", as used herein, unless otherwise indicated, refers to "heterocycloalkyl-O", wherein "heterocycloalkyl" is as defined above.

The term "heteroaryloxy", as used herein, unless otherwise indicated, refers to "heteroaryl-O-", wherein "heteroaryl" is as defined above.

Unless otherwise indicated, all of the above groups derived from hydrocarbons may be optionally substituted with one or more halogen atoms (e.g., -CH₂F、-CHF₂、-CF₃-PhCl, etc.).

The term "one or more" substituents, or "at least one" substituent, as used herein, means, unless otherwise indicated, from 1 to the maximum possible number of substituents based on the number of available bonding sites. (examples of one or more or at least one substituent include, but are not limited to, 1 to 10 substituents, or 1 to 6 substituents or 1 to 3 substituents).

Unless otherwise indicated, all of the above groups derived from hydrocarbons can have up to about 1 to about 20 carbon atoms (e.g., C)₁-C₂₀Alkyl radical, C₂-C₂₀Alkenyl radical, C₃-C₂₀Cycloalkyl, (3-20 membered) heterocycloalkyl, C₆-C₂₀Aryl, (5-20 membered) heteroaryl, etc.), or 1 to about 15 carbon atoms (e.g., C)₁-C₁₅Alkyl radical, C₂-C₁₅Alkenyl radical, C₃-C₁₅Cycloalkyl, (3-15 membered) heterocycloalkyl, C₆-C₁₅Aryl, (5-15 membered) heteroaryl, etc.), or 1 to about 12 carbon atoms, or 1 to about 8 carbon atoms, or 1 to about 6 carbon atoms.

Such as those described above, derived from the compounds listed above, may be C-linked or N-linked where possible. For example, a group derived from pyrrole may be pyrrol-1-yl (N-linked) or pyrrol-3-yl (C-linked). The term referring to a group also includes all possible tautomers.

In one aspect of the invention, stereochemistry is defined as formula II or formula III:

formula II formula III

In one aspect of the invention, R₁Is imidazolyl optionally substituted with methyl.

In another aspect, Z is (C)₆-C₁₄) Aryl, and R₄Or R₅Each independently is H, halogen, -CF₃、-OCF₃、(C₆-C₁₄) Aryl or (C)₆-C₁₄) An aryloxy group.

In yet another aspect of the invention, R₂、R₃And A is hydrogen.

In another aspect, Y is (C)₁-C₆) Alkyl, (C)₃-C₆) Cycloalkyl, (3-6 membered) heterocycloalkyl or-CH₂-(C₃-C₆) A cycloalkyl group; wherein Y is optionally substituted by halogen, OH, -SO₂R₁₀、-C(＝O)R₁₀Or CH₂CH₂CF₃And (4) substitution.

In another aspect of the invention, the compounds of formula I have the following structure:

wherein R is²-R5, Q, Z, Y and a are as defined above.

Specific embodiments of the present invention are shown in the following examples.

The compounds of formula I may have optical centers and thus may give rise to different enantiomeric and diastereomeric configurations. The present invention includes all enantiomers, diastereomers and other stereoisomers of these compounds of formula I, as well as racemic compounds and racemic mixtures and other mixtures of stereoisomers thereof.

Pharmaceutically acceptable salts of the compounds of formula I include acid addition salts and base salts thereof.

Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include, but are not limited to, acetate, adipate, aspartate, benzoate, benzenesulfonate, bicarbonate/carbonate, bisulfate/sulfate, borate, camphorsulfonate, citrate, cyclamate, edisylate (edisylate), ethanesulfonate (esylate), formate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate, oxybenzoate (hibenzate), hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mandelate, methanesulfonate, methylsulfate, naphthenate (naphylate), 2-naphthalenesulfonate, nicotinate, nitrate, orotate (orotate), oxalate, palmitate, pamoate, Phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, salicylate, sucrose, stearate, succinate, sulfonate, tannate, tartrate, tosylate, trifluoroacetate and xinofoate.

Suitable base salts are formed from bases which form non-toxic salts. Examples include, but are not limited to, aluminum, arginine, benzathine, calcium, choline, diethylamine, diethanolamine, glycinate, lysine, magnesium, meglumine, ethanolamine, potassium, sodium, tromethamine salts and zinc salts.

Hemisalts of acids and bases, such as hemisulfate and hemicalcium salts, may also be formed.

For a review of suitable Salts, see Stahl and Wermuth, Handbook of pharmaceutical Salts: properties, Selection, and Use (handbook of salts of pharmaceutical salts: Properties, Selection, and applications) (Wiley-VCH, 2002).

Pharmaceutically acceptable salts of the compounds of formula I can be prepared by one or more of three methods:

(i) reacting a compound of formula I with a desired acid or base;

(ii) removing acid or base labile protecting groups from a suitable precursor of a compound of formula I or opening a suitable cyclic precursor (e.g. a lactone or lactam) using a desired acid or base; or

(iii) One salt of the compound of formula I is converted to another salt by reaction with a suitable acid or base or by passage through a suitable ion exchange column.

All three reactions are generally carried out in solution. The resulting salt may be precipitated and collected by filtration, or may be recovered by evaporation of the solvent. The degree of ionization of the resulting salt can vary from fully ionized to almost unionized.

The compounds of the present invention may exist in a continuous solid state, from a fully amorphous state to a fully crystalline state. The term "amorphous" refers to a state in which a material lacks long-range order at the molecular level and may exhibit the physical properties of a solid or liquid depending on temperature. In general, these materials do not exhibit a characteristic X-ray diffraction pattern and, while exhibiting the properties of a solid, are more formally described as liquids. Upon heating, a change in the solid to liquid properties occurs, characterized by a change in state, typically a secondary order change ("glass transition"). The term "crystalline" refers to a solid phase of a material having a regular ordered internal structure at the molecular level and exhibiting a characteristic X-ray diffraction pattern with defined peaks. These materials also exhibit liquid properties when heated sufficiently, but the change from solid to liquid is characterized by a phase change, typically a first order phase change ('melting point').

The compounds of the present invention may also exist in unsolvated and solvated forms. The term "solvate" as used herein is a molecular complex that includes a compound of the present invention and one or more pharmaceutically acceptable solvent molecules (e.g., ethanol). When the solvent is water, the term "hydrate" is used.

The currently accepted system of classification for organic hydrates is the definition of separation sites, channels or metal-ion coordinated hydrates-see Polymorphism in pharmaceutical solids polymorphisms of k.r. morris (h.g. brittain eds., Marcel Dekker, 1995). The water molecules are separated by inserting organic molecules into the hydrate of the separation site, and are not in direct contact with each other. In channel hydrates, water molecules are present in lattice channels where they are in close proximity to other water molecules. In the metal-ion complex hydrate, water molecules are bonded to metal ions.

When solvents or water are intimately bound, the ligands have a well-defined stoichiometry which is independent of humidity. However, when the solvent or water combination is weak, as in channel solvates and hygroscopic compounds, the water/solvent content will depend on the humidity and drying conditions. In such a case, the non-stoichiometry would be normal.

The compounds of the invention may also be present in a mesomorphic state (mesophase or liquid crystal) when subjected to suitable conditions. A mesomorphic state is an intermediate state between a true crystalline state and a true liquid state (either melt or solution). The appearance of mesogenic phenomena caused by a change in temperature is called 'thermotropic' and the appearance of mesogenic phenomena caused by the addition of a second component, such as water or another solvent, is called 'lyotropic'. Compounds having the potential to form lyotropic mesophases are referred to as 'amphiphilic' and are composed of molecules having ions (e.g. -COO)^-Na⁺、-COC^-K⁺or-SO₃ ^-Na⁺) Or non-ionic (e.g. -N)^-N⁺(CH₃)₃) The molecular constitution of the polar head group. See also N.H.Hartshorn and A.Stuart, crystallography and the polarising Microscope, 4th Edition (Edward Arnold, 1970).

All references hereinafter to compounds of formula I include references to salts, solvates, multicomponent ligands and liquid crystals thereof, and to solvates, multicomponent ligands and liquid crystals of salts thereof.

The compounds of the invention include compounds of formula I as hereinbefore defined, including all polymorphs and crystal habit thereof, prodrugs and isomers thereof (including optical, geometric and tautomeric isomers) and isotopically labelled compounds of formula I as hereinafter defined.

So-called 'prodrugs' of the compounds of formula I as described above are also included within the scope of the present invention. Thus, certain derivatives of the compounds of formula I which themselves have little or no pharmacological activity are capable of being converted, e.g. by hydrolytic cleavage, into compounds of formula I having the desired activity when administered in vivo or in vivo. These derivatives are referred to as 'prodrugs'. Further information on the use of prodrugs can be found in Pro-drugs as Novel Delivery Systems, Vol.14, ACS Symposium Series (T. Higuchi and W.Stella) and Bioreproducible Carriers in Drug Design, Pergamon Press, 1987(Ed. E.B.Roche, American pharmaceutical Association).

Prodrugs according to the invention may be generated, for example, by replacing suitable functional groups present in a compound of formula I with certain moieties known to those skilled in the art as 'precursor-moieties', for example, as described in Design of Prodrugs of h.

Some examples of prodrugs according to the invention include, but are not limited to:

(i) when the compound of formula I contains a carboxylic acid function (-COOH), esters thereof, for example wherein the hydrogen of the carboxylic acid function of the compound of formula (I) is replaced by (C)₁-C₈) Alkyl substituted compounds;

(ii) when the compound of formula I contains an alcohol function (-OH), the ether thereof, for example, wherein the hydrogen of the alcohol function of the compound of formula I is replaced by (C)₁-C₆) Alkanoyloxymethyl-substituted compounds; and

(iii) when the compounds of formula I contain a primary or secondary amino function (-NH)₂or-NHR, where R.noteq.H), amides thereof, for example where, as the case may be, one or both hydrogens of the amino function of the compound of formula I are replaced by (C)₁-C₁₀) Alkanoyl substituted compounds.

Further examples of substituents according to the above examples and examples of other types of prodrugs can be found in the references mentioned above.

Furthermore, certain compounds of formula I may themselves act as prodrugs of other compounds of formula I.

Metabolites of the compounds of formula I are also included within the scope of the present invention, i.e. compounds which are formed in vivo after administration of the drug. Some examples of metabolites according to the invention include, but are not limited to:

(i) when the compound of formula I contains a methyl group, the hydroxymethyl derivative thereof (-CH)₃→-CH₂OH)；

(ii) When the compound of formula I contains an alkoxy group, its hydroxy derivative (-OR → -OH);

(iii) when the compound of formula I contains a tertiary amino group, its secondary amino derivative (-NR)¹R²→-NHR¹or-NHR²)；

(iv) When the compound of formula I contains a secondary amino group, its primary amino derivative (-NHR)¹→-NH₂)；

(v) When the compound of formula I contains a phenyl moiety, its phenol derivative (-Ph → -PhOH); and

(vi) when the compound of formula I contains an amide group, its carboxylic acid derivative (-CONH)₂→COOH)。

The compounds of formula I containing one or more asymmetric carbon atoms may exist as two or more stereoisomers. When the compounds of formula I contain an alkenyl or alkenylene group, geometric cis/trans (or Z/E) isomers are possible. When structural isomers interconvert via a low energy barrier, tautomerism ('tautomerism') can occur. In compounds of the formula I containing, for example, imino, keto or oxime groups, proton tautomerism can be assumed, or in compounds containing aromatic moieties, so-called valence tautomerism can be assumed. It follows that a single compound may exhibit more than one type of isomerism.

All stereoisomers, geometric isomers and tautomeric forms of the compounds of formula I, including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof, are included within the scope of the invention. The invention also includes acid addition or base salts in which the counterion is optically active (e.g., d-lactate or l-lysine) or racemic (dl-tartrate or dl-arginine).

The cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, such as chromatography and fractional crystallisation.

Conventional techniques for preparing/separating the individual enantiomers include chiral synthesis from suitable optically pure precursors, or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral High Pressure Liquid Chromatography (HPLC).

Alternatively, the racemate or racemic mixture (or racemic precursor) may be reacted with a suitable optically active compound, for example an alcohol, or, in the case of compounds of formula I containing an acidic or basic moiety, a base or acid, for example 1-phenylethylamine or tartaric acid. The resulting diastereomeric mixture can be separated by chromatography and/or fractional crystallization and one or both of the diastereomers converted to the corresponding pure enantiomers in a manner well known to the skilled artisan.

The chiral compounds of the invention (and chiral precursors thereof) can be obtained in enantiomerically enriched form on asymmetric resins using chromatography (typically HPLC) with a mobile phase consisting of a hydrocarbon (typically heptane or hexane) containing from 0 to 50 vol% isopropanol (typically from 2 to 20 vol%), and from 0 to 5 vol% alkylamine (typically 0.1% diethylamine). The concentration of the eluent provides a concentrated mixture.

When any racemate crystallizes, two different types of crystals are possible. The first type is the racemic compound mentioned above (true racemate), in which a crystal of one homogeneous form containing equimolar amounts of the two enantiomers is produced. The second type is a racemic mixture or aggregate, in which equimolar amounts of two forms of crystals are produced, each crystal comprising a single enantiomer.

Although the two crystalline forms present in the racemic mixture have the same physical properties, they may have different physical properties compared to the true racemate. The racemic mixture can be separated by conventional techniques known to those skilled in the art. See, e.g., stenoochemistry of Organic Compounds (Wiley, 1994) by e.l.eliel and s.h.wilen.

The present invention includes all pharmaceutically acceptable isotopically-labelled compounds of formula I in which one or more atoms are replaced by an atom having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature.

Examples of isotopes suitable for inclusion in the compounds of the invention include, but are not limited to: isotopes of hydrogen, e.g.²H and³h; carbon, e.g.¹¹C、¹³C and¹⁴c; chlorine, e.g.³⁶Cl; fluorine, e.g.¹⁸F; iodine, e.g.¹²³I and¹²⁵i; nitrogen, e.g.¹³N and¹⁵n; oxygen, e.g.¹⁵O、¹⁷O and¹⁸o; phosphorus, e.g.³²P; and sulfur, e.g.³⁵S。

Certain isotopically-labeled compounds of formula I, for example those into which a radioactive isotope has been incorporated, are useful in drug and/or substrate tissue distribution studies. Particularly useful for this purpose are the radioactive isotopes tritium, i.e.³H, and carbon-14, i.e.¹⁴C because they are easy to incorporate and easy to detect.

With heavier isotopes such as deuterium (i.e.²H) Substitution may provide certain therapeutic advantages due to higher metabolic stability, e.g., increased in vivo half-life or reduced dosage requirements, and may therefore be preferred in some circumstances.

With positron-emitting isotopes such as¹¹C、¹⁸F、¹⁵O and¹³n substitution, useful in Positron Emission Tomography (PET) studies to test substrate receptor occupancy.

Isotopically-labelled compounds of formula I can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying examples and preparations using a suitable isotopically-labelled reagent in place of the unlabelled reagent employed previously.

Pharmaceutically acceptable solvates according to the invention include those compounds in which the crystallization solvent may be isotopically substituted, e.g., D₂O、d₆-acetone, d₆-DMSO。

When preparing the compounds of formula I according to the present invention, it is disclosed to the skilled person that the form of the compounds of formula II is routinely selected, which provides the best combination of technical features for the purposes of the present invention. These characteristics include, but are not limited to, melting point, solubility, processability, and yield of intermediate forms, as well as the ease with which the product can be purified in isolation.

The present invention also relates to a method of treating a mammal, including a human, selected from the group consisting of: psychosis, schizophrenia, conduct disorder, disruptive behavior disorder, bipolar disorder, psychotic episodes of anxiety, anxiety and psychosis comorbidities, psychotic mood disorders such as major depressive disorder; affective disorders and co-morbidities such as acute mania or depression with bipolar affective disorder and affective disorder with schizophrenia, behavioral manifestations of mental retardation, conduct disorder and autism; dyskinesias such as Tourette's syndrome, akinesia-strauss syndrome, dyskinesias and parkinson's disease co-morbidities, tardive dyskinesia and other drug-induced and neurodegenerative-based dyskinesias; attention deficit hyperactivity disorder; cognitive disorders such as dementia (including age-related dementia, and senile dementia of the alzheimer's type) and memory disorders in a mammal in need of such treatment comprising administering to the mammal an amount of a compound of formula I or a pharmaceutically acceptable salt thereof effective to treat such conditions or disorders.

The present invention also relates to a pharmaceutical composition for the treatment of a mammal, including a human, selected from the following dysfunctions or conditions: psychosis, schizophrenia, conduct disorder, disruptive behavior disorder, bipolar disorder, psychotic episodes of anxiety, anxiety and psychotic comorbidities, psychotic affective disorders such as major depressive disorder; affective disorders and co-morbidities such as acute mania or depression with bipolar affective disorder and affective disorder with schizophrenia, behavioral manifestations of mental retardation, conduct disorder and autism; dyskinesias such as Tourette's syndrome, akinesia-strauss syndrome, dyskinesias and parkinson's disease co-morbidities, tardive dyskinesia and other drug-induced and neurodegenerative-based dyskinesias; attention deficit hyperactivity disorder; cognitive disorders such as dementia (including age-related dementia, and senile dementia of the alzheimer's type) and memory disorders comprising an amount of a compound of formula I or a pharmaceutically acceptable salt thereof effective to treat such dysfunction or disorder.

The present invention also relates to a method of treating a mammal, including a human, selected from the group consisting of: psychosis, schizophrenia, conduct disorder, disruptive behavior disorder, bipolar disorder, psychotic episodes of anxiety, anxiety and psychotic comorbidities, psychotic affective disorders such as major depressive disorder; affective disorders and co-morbidities such as acute mania or depression with bipolar affective disorder and affective disorder with schizophrenia, behavioral manifestations of mental retardation, conduct disorder and autism; dyskinesias such as Tourette's syndrome, akinesia-strauss syndrome, dyskinesias and parkinson's disease co-morbidities, tardive dyskinesia and other drug-induced and neurodegenerative-based dyskinesias; attention deficit hyperactivity disorder; cognitive disorders such as dementia (including age-related dementia, and senile dementia of the alzheimer's type) and memory disorders in a mammal in need of such treatment comprising administering to the mammal a glycine transport inhibiting amount of a compound of formula I or a pharmaceutically acceptable salt thereof.

The present invention also relates to a pharmaceutical composition for the treatment of a mammal, including a human, selected from the following dysfunctions or conditions: psychosis, schizophrenia, conduct disorder, disruptive behavior disorder, bipolar disorder, psychotic episodes of anxiety, anxiety and psychotic comorbidities, psychotic affective disorders such as major depressive disorder; affective disorders and co-morbidities such as acute mania or depression with bipolar affective disorder and affective disorder with schizophrenia, behavioral manifestations of mental retardation, conduct disorder and autism; dyskinesias such as Tourette's syndrome, akinesia-strauss syndrome, dyskinesias and parkinson's disease co-morbidities, tardive dyskinesia and other drug-induced and neurodegenerative-based dyskinesias; attention deficit hyperactivity disorder; cognitive disorders such as dementia (including age-related dementia, and senile dementia of the alzheimer's type) and memory disorders comprising a glycine transport inhibiting amount of a compound of formula I or a pharmaceutically acceptable salt thereof.

The term "treating" as used herein means reversing, alleviating or inhibiting the progression of the disease, disorder or condition to which the term applies, or one or more symptoms of such disease, disorder or condition. As used herein, "treating" or "treatment" may also refer to reducing the likelihood or incidence of a disease, disorder or condition occurring in a mammal as compared to a control population not receiving treatment, or as compared to the same mammal prior to treatment. For example, "treating" as used herein may refer to preventing a disease, disorder or condition, and may include delaying or preventing the onset of a disease, disorder or condition, or delaying or avoiding symptoms associated with a disease, disorder or condition. As used herein, "treating" or "treatment" may also refer to reducing the severity of a disease, disorder or condition, or the symptoms associated with such disease, disorder or condition, prior to the mammal suffering from the disease, disorder or condition. This aspect of preventing or lessening the severity of a disease, disorder or condition prior to suffering therefrom involves administering to a subject suffering therefrom who is not in the course of administration a composition of the invention as described herein. As used herein, "treating" or "treatment" may also refer to preventing the recurrence of a disease, disorder or condition, or one or more symptoms associated with such a disease, disorder or condition. The terms "treatment" and "therapeutically" as used herein refer to the act of treating, as defined above.

The compounds of the present invention exhibit glycine transport inhibitory activity and are therefore of value in the treatment of a variety of clinical conditions characterized by defects in glutamatergic neurotransmission in mammalian subjects, particularly humans. These disorders include positive and negative symptoms of schizophrenia and other psychoses, as well as cognitive deficits.

The compounds of the present invention may be administered to a mammal by oral, parenteral (e.g., subcutaneous, intravenous, intramuscular, intrasternal, and infusion techniques), rectal, intranasal, or topical routes. Generally, most of these compounds are administered to humans at a dosage of about 1mg to about 2000mg per day, although some variation will necessarily occur depending on the weight and condition of the subject being treated and the particular route of administration chosen. However, the most preferred dosage levels employed range from about 0.1mg to about 20mg per kilogram of body weight per day. Nevertheless, variations will occur depending upon the animal species being treated and its individual response to the drug, as well as the type of pharmaceutical formulation selected and the time period and interval at which such administration is carried out. In some instances, dosage levels below the lower limit of the aforesaid range may be more suitable, while in other cases larger doses may be employed without causing any harmful side effects, provided that such higher dosage levels are first divided into several small doses for administration throughout the day.

In one embodiment, the compounds of the invention are administered as adjunctive therapy with known antipsychotic drugs, such as Ziprasidone (Geodon), clozapine, molindone, loxapine, pimozide, risperidone, Olanzapine (Olanzapine), Remoxipride (Remoxipride), Sertindole (Sertindole), Amisulpride (Amisulpride), Quetiapine (quietiapine), prochlorperazine, fluphenazine, trifluoperazine (trifluroperazine), methiopyridazine, haloperidol, chlorpromazine, flupentixol and pipothiazine.

In another embodiment, the compounds of the present invention may also be used in combination with: CNS drugs such as antidepressants (e.g. sertraline (sertraline)), anti-parkinson drugs (e.g. selegiline (deprenyl), L-dopa, ropinirole (Requip), Mirapex, MAOB inhibitors such as selegine and rasagiline (rasagiline), comP inhibitors such as tolcapone (tasimar), a-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists, nicotinic agonists, dopamine agonists and inhibitors of neuronal nitric oxide synthase), anti-alzheimer drugs such as donepezil (donepezil), tacrine, alpha 2 delta inhibitors, COX-2 inhibitors, gaba pentatenoid, propentofylline (properfylline) or metryfonate, and antipsychotics such as PDE10 inhibitors, 5HT2C agonists, alpha 7 nicotinic receptor agonists, nicotinic 1 antagonists and compounds with antagonistic activity at the dopamine D2 receptor.

The compounds of the present invention may be administered by the routes previously set forth above, alone or in combination with a pharmaceutically acceptable carrier or diluent, and such administration may be carried out in single or multiple doses. More specifically, the novel therapeutic agents of the present invention may be administered in a variety of different dosage forms, i.e., they may be incorporated with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, emulsions, salves, suppositories, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media, and various non-toxic organic solvents, and the like. Furthermore, oral pharmaceutical compositions may be suitably sweetened with sugar and/or flavored. Typically, the therapeutically effective compound of the present invention is present in these dosage forms at a concentration level in the range of about 5.0 wt% to about 70 wt%.

For oral administration, tablets containing various excipients, such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine, may be employed along with various disintegrants, such as starch, preferably corn, potato or tapioca starch, alginic acid and certain complex silicates, together with granulation binders such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are commonly used for tableting. Solid compositions of a similar type may also be used as fillers in gelatin capsules; preferred materials in this regard also include lactose or milk sugar, as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and if desired, emulsifying and/or suspending agents, as well as diluents such as water, ethanol, propylene glycol, glycerin, and the like, and various similar combinations thereof.

For parenteral administration, solutions of the compounds of the invention in sesame or peanut oil or aqueous propylene glycol solutions may be used. The aqueous solution should be suitably buffered (preferably to a pH > 8) if necessary so that the liquid diluent first becomes isotonic. These aqueous solutions are suitable for intravenous injection. The oily solutions are suitable for intra-articular, intramuscular and subcutaneous injection. The preparation of all these solutions is readily accomplished under sterile conditions by standard pharmaceutical techniques well known to those skilled in the art. In addition, when treating inflammatory conditions of the skin, it is also possible to administer the compounds of the invention topically, which administration can preferably be accomplished by creams, gels, pastes, ointments and the like, according to standard pharmaceutical practice.

Compounds of the invention were detected using a GlyT1 radioligand binding assay as follows:

preparation of test compound: the compounds were dissolved in DMSO, sonicated if necessary, diluted to a concentration of 0.2mM in DMSO and then diluted with deionized water to a concentration of 10. mu.M.

Tissue preparation solution: GlyT1c transporter was expressed in HEK-293 cells, the frozen cell pellet weighed, and 1 gram of the pellet was homogenized (polyron) in 30mL assay buffer (50mM Tris base, 120mM NaCl and 5mM KCl, pH adjusted to 7.4 with 6N HCl). The mixture was centrifuged at 40000G for 10min, the supernatant discarded, and the pellet resuspended at a wet weight of 1mg per 25. mu.L assay buffer.

And (4) assay: the assay incubations were performed in 96-well plates (Beckman 2mL polypropylene) for 60 minutes at room temperature, which were vortexed during the addition of the tissue preparation. mu.L of test drug solution or control, 200. mu.L of 0.7nM [3H ] -NPTS (Lowe, John A.; Drozda, Susan E.; Fisher, Katherine; Strick, Christine; Lebel, Lorraine; Schmidt, Christopher; Hiller, Donna; Zandi, Kathlen S. [3H ] - (R) -NPTS, aradioligand for the type 1 glycine transporter ([3H ] - (R) -NPTS, radioligand of type 1 glycine transporter), Bioorganic & Medicinal Chemistry Letters (2003), 13 (1297), 1291-), and 25. mu.L of tissue were added to each well. Assay plates were filtered using a Brandel cell harvester with GF/B filters, which were washed with 3 x 1.5mL assay buffer, air dried overnight, and counted the next day on a LKB β plate counter.

The compounds of the invention analyzed by this assay have been found to have significant activity in inhibiting glycine reuptake by synaptosomes, with an inhibition of more than 20% at 1 μ M.

The compounds of formula I can be prepared by the methods described below, as well as by synthetic methods well known in the art of organic chemistry, or by variations and derivatives well known to those of ordinary skill in the art. Preferred methods include, but are not limited to, the methods described below.

In any of the synthetic sequences below, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This can be accomplished by conventional protecting Groups, such as T.W. Greene, Protective Groups in Organic Chemistry, John Wiley & Sons, 1981; and T.W.Greene and P.G.M.Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1991, which are incorporated herein by reference.

The compounds of formula I or pharmaceutically acceptable salts thereof may be prepared according to the following reaction schemes I through V, as discussed below. A, Q, Y, Z and R unless otherwise specified₁To R₅As specified above. Isolation and purification of the product is accomplished by standard procedures, which are well known to those of ordinary skill in the chemical arts.

The following reaction schemes are examples of methods for preparing compounds of formula I.

Scheme I illustrates a process for preparing a compound having the basic structure of formula I, wherein A is hydrogen, Y is hydrogen, and Q, Z and R₁To R₈As specified above.

With reference to reaction scheme I, the compounds of formula (I) [ SynLett, 1996, 1097]In the presence of a suitable base such as triethylamine, for example, in the presence of CH₂Cl₂In a solvent (BOC)₂O treatment produces the desired carbamate of formula (II). Under Swern conditions in the presence of a suitable base such as Triethylamine (TEA) or Diisopropylethylamine (DIEA) in a solvent such as CH₂Cl₂Or 1, 2-Dichloroethane (DCE), oxidizing the primary alcohol with DMSO and oxalyl chloride (oxayl chloride) at a temperature of-78 ℃ to room temperature, preferably at about room temperature, to give the corresponding aldehyde (not shown). Other suitable oxidizing agents for such conversionIncluding TPAP/NMO or PCC.

With appropriately substituted amine reagents of formula (III) and a suitable reducing agent such as NaBH₄Treating the aldehyde in a solvent such as MeOH at a temperature from-5 ℃ to room temperature, preferably at about room temperature, produces the desired amine of formula (IV). Other suitable reducing agents for this reaction include NaCNBH₃Or NaHB (OAc)₃In the presence of, for example, MeOH, CH₂Cl₂Or in a solvent for DCE. Other suitable conditions for this conversion include the use of an amine reagent (III) in CH₂Cl₂Or DCE, treating the corresponding aldehyde at room temperature in the presence of 4A molecular sieves and a base such as TEA, followed by NaBH₄Or NaHB (OAc)₃And (6) processing.

Reaction scheme I

By reacting an appropriately substituted acid chloride reagent of formula (V) in the presence of a suitable base such as DIEA, pyridine or TEA in a solvent such as DCE or CH₂Cl₂The compound of formula (VII) may be prepared by treating the amine of formula (IV) at a temperature from room temperature to about reflux temperature, preferably at about room temperature. Alternatively, compounds of formula (VII) may be prepared by treating an amine of formula (IV) with a carboxylic acid of formula (VI) and a suitable coupling reagent such as HOBT, HBTU, DCC, EDCl and the like to yield the corresponding amide of formula (VII). Finally, the compounds of formula (VIII) can be prepared by using TFA or HCl in a solvent such as EtOAc, dioxane, CH₂Cl₂Or DCE, treating the carbamate of formula (VII) at a temperature from 0 ℃ to about room temperature, preferably at about room temperature, to produce the corresponding amine of formula (VIII).

Reaction scheme II illustrates a process for preparing compounds having the basic structure of formula I, wherein A is hydrogen, Y, Q, Z and R₁-R₆As described above.

Reference is made to the following reactionIn accordance with scheme II, compounds of formula (IX) can be prepared by reacting an appropriately substituted aldehyde or ketone with a reducing agent such as NaHB (OAc)₃In a solvent such as CH₂Cl₂Or DCE, treating the amine of formula (VIII) at a temperature of from 0 ℃ to about room temperature, preferably at about room temperature, to produce the corresponding amine of formula (IX). Other suitable conditions for this process include treating the amine of formula (VIII) with an aldehyde in toluene at about reflux temperature; then using NaBH₄Treatment in a solvent such as MeOH yields the corresponding amine of formula (IX). With aldehydes and NaCNBH₃Treatment of an amine of formula (VIII) in a solvent such as MeCH may also yield the corresponding amine of formula (IX).

Reaction scheme II

Reaction scheme III illustrates a different method for preparing compounds having the basic structure of formula I, wherein A is hydrogen, Y, Q, Z and R₁-R₅As described above. R₉Is cycloalkyl, - (CH)₂)_o-R₆、-CH(R₆) or-C (R)₆)₂。

Referring to reaction scheme III below, compounds of formula (VIII) can be treated with an epoxide reagent of formula (X) in the presence of a suitable base such as triethylamine in a solvent such as methanol or ethanol at a temperature from room temperature to about reflux temperature, preferably at about reflux temperature, to yield compounds of formula (IX).

Reaction scheme III

Reaction scheme IV below illustrates the preparation of a compound having the basic structure of formula IFurther methods of compounds wherein A is hydrogen, and Y, Q, Z and R₁-R₅As described above.

Referring to reaction scheme IV below, compounds of formula (XIII) can be treated with a suitable base such as NaH or KH, and an appropriately substituted alkylating agent of formula (XI) (where L is a suitable leaving group such as Cl, Br, I, OMs, OTs) in a solvent such as THF or diethyl ether at a temperature from 0 ℃ to about room temperature, preferably at about room temperature, to give compounds of formula (IX).

Reaction scheme IV

Scheme V below illustrates other methods for preparing compounds having the basic structure of formula I, wherein A is hydrogen, and Y, Q, Z and R₁-R₈As described above.

Referring to reaction scheme V below, compounds of formula (VIII) can be treated with an appropriately protected α -bromoester derivative of formula (X), such as α -bromobenzyl acetate, in the presence of a base such as potassium carbonate, a suitable ammonium salt such as tetraethylammonium chloride and a suitable solvent such as dimethylformamide, at room temperature to give the desired compound of formula (XI). The compound of formula (XI) can be treated with a suitable palladium catalyst, such as palladium hydroxide, in a solvent, such as methanol or ethanol, to produce the compound of formula (XII). Finally, compounds of formula (XIV) can be prepared by treating an acid of formula (XII) with primary and secondary amines of formula (XIII) in the presence of a suitable coupling agent such as O-benzotriazol-1-yl-N, N' -tetramethyluronium Hexafluorophosphate (HBTU) and triethylamine to yield the desired compound of formula (XIV).

Reaction scheme V

The following examples and preparations illustrate the invention. It is to be understood that the invention as described in the detailed description and claims hereof is not to be limited to the details of the following examples.

Examples

Preparation example 1

6-hydroxymethyl-3-aza-bicyclo [3.1.0]Hexane-3-carboxylic acid tert-butyl ester

To (3-aza-bicyclo [ 3.1.0)]Hex-6-yl) -methanol-HCl (11.8gm, 78.7mmol) in 350mL anhydrous CH₂Cl₂To the solution of (1), Et was added at room temperature₃N (32.9mL, 236mmol) was added in portions (BOC)₂O (18.9gm, 86.6 mmol). The reaction was stirred at room temperature for 18 hours. The mixture was washed with saturated NaHCO₃Washed with water, brine and anhydrous MgSO₄And (5) drying. The mixture was filtered and concentrated under reduced pressure to give a crude material which was flash chromatographed with 10% MeOH/CH₂Cl₂And (5) purifying. Collecting fractions containing the product and concentrating to obtain 6-hydroxymethyl-3-aza-bicyclo [ 3.1.0%]Hexane-3-carboxylic acid tert-butyl ester (15.6 gm). 400MHz¹H NMR(CDCl₃)δ 3.4-3.6(m，4H)，3.2-3.7(m，2H)，1.72(brs，1H)，1.4-1.4(m，10H)，0.9-0.9(m，1H)；MS(M+1)213.2。

Preparation example 2

6-formyl-3-aza-bicyclo [3.1.0]Hexane-3-carboxylic acid tert-butyl ester

To oxalyl chloride (7.8mL, 89.5mmol) in 370mL anhydrous CH₂Cl₂To a stirred solution of (3), DMSO (13.8mL, 193.9mmol) was added dropwise under nitrogen at-78 ℃. After 10 minutes, 72mL of anhydrous CH was added₂Cl₂6-hydroxymethyl-3-aza-bicyclo [3.1.0] in (1)]Hexane-3-carboxylic acid tert-butyl ester (15.9gm, 74.5 mmol). The mixture is stirred 30After min, triethylamine (52.0mL, 372.9mmol) was added and the mixture was slowly heated to 0 ℃ over 1 h. The mixture was concentrated and the resulting solid was charged to saturated NaHCO₃And EtOAc, the layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried, filtered and concentrated to give the crude product, 6-formyl-3-aza-bicyclo [3.1.0] in quantitative]Hexane-3-carboxylic acid tert-butyl ester (15.8gm) which was used in the next step without purification. 400MHz¹H NMR(CDCl₃)δ9.4(d，J＝4.1Hz，1H)，3.6(dd，J＝11.2Hz，37.8Hz，2H)，3.4(d，J＝9.95，2H)，2.1(m，2H)，1.8-1.7(q，J＝3.32Hz，1H)，1.4(s，9H)；GCMS(M+0)211.0。

Preparation example 3

6- [ (3-trifluoromethoxy-benzylamino) -methyl]-3-aza-bicyclo [3.1.0]Hexane-3-carboxylic acid tert-butyl Esters

To a stirred solution of the aldehyde prepared above (1.0g, 4.7mmol) in 9.5mL MeOH was added 3-trifluoromethoxy-benzylamine (0.7mL, 4.7 mmol). The reaction mixture was stirred at room temperature for 24 hours. Sodium borohydride (0.4g, 9.5mmol) was then added and the reaction mixture stirred for an additional 24 hours. The reaction was concentrated under reduced pressure, and the resulting material was added to 1N NaOH and CH was added₂Cl₂And (4) extracting. The combined organic layers were over anhydrous MgSO₄Drying, filtration and concentration under reduced pressure gave 1.8gm of the desired amine, which was used without purification. 6- [ (3-trifluoromethoxy-benzylamino) -methyl]-3-azabicyclo [3.1.0]Hexane-3-carboxylic acid tert-butyl ester 400MHz¹H NMR(CDCl₃)δ7.3(t，J＝7.8Hz，1H)，7.2(m，1H)，7.2(s，1H)，7.1-7.0(m，1H)，3.8(s，2H)，3.5(dd，J＝39.4Hz，10.8 Hz，2H)，3.8(t，J＝10.8Hz，2H)，2.5(dt，J＝6.0Hz，25.7Hz，2H)，1.4(s，9H)，1.3(m，2H)0.8-0.7(m，1H)；MS(M+1)387.3。

The following compounds were prepared using the procedure described in preparation 3.

6- [ (3-trifluoromethyl-benzylamino) -methyl]-3-aza-bicyclo [3.1.0]Hexane-3-carboxylic acid tert-butyl ester

400MHz ¹H NMR(CDCl₃)δ7.5(s，1H)，7.5-7.2(m，3H)，3.8(s，2H)，3.5(dd，J＝37.7Hz，10.8Hz，2H)，3.2(m，2H)，2.5(dt，J＝17.0Hz，5.4Hz，2H)，1.4(s，9H)，1.3-1.2(m，2H)0.8-0.7(m，1H)；MS(M+1)371.3。

6- [ (3-chloro-benzylamino) -methyl]-3-aza-bicyclo [3.1.0]Hexane-3-carboxylic acid tert-butyl ester

400MHz ¹H NMR(CDCl₃)δ7.3(s，1H)，7.2-7.1(m，3H)，3.8(s，2H)，3.5(dd，J＝37.3Hz，10.8Hz，2H)，3.3-3.3(m，2H)，2.6-2.5(m，2H)，1.4(m，9H)，1.3(m，2H)0.8-0.7(m，1H)；MS(M+1)337.2。

6- [ (4-fluoro-3-trifluoromethyl-benzylamino) -methyl]-3-aza-bicyclo [3.1.0]Hexane-3-carboxylic acid tert-butyl ester Butyl ester

400MHz ¹H NMR(CDCl₃)δ7.6-7.5(m，1H)，7.5-7.4(m，1H)^J，7.2(s，1H)，3.8(s，1H)3.6-3.5(m，4H)，2.5-2.5(m，2H)，1.4(s，9H)，1.3-1.2(m，2H)0.8-0.7(m，1H)；MS(M+1)389.3。

6- [ (3-chloro-4-fluoro-benzylamino) -methyl]-3-aza-bicyclo [3.1.0]Hexane-3-carboxylic acid tert-butyl ester

400MHz ¹H NMR(CDCl₃)δ7.3-7.4(m，1H)；7.0-7.2(m，2H)；3.7(3，2H)；3.4-3.6(m，2H)；3.3-3.4(m，2H)；2.4-2.6(m，2H)；1.4(m，9H)；1.3(m，2H)；0.8(m，1H)。

Preparation example 4

6- { { (1-methyl-1H-imidazole-4-carbonyl) - (3-trifluoromethoxy-benzyl) -amino]-methyl } -3-aza- Bicyclo [3.1.0]Hexane-3-carboxylic acid tert-butyl ester

6- [ (3-trifluoromethoxy-benzylamino) -methyl ] amino prepared above]-3-aza-bicyclo [3.1.0]Hexane-3-carboxylic acid tert-butyl ester (5.9gm, 15.4mmol) in 192mL CH₃CN to a stirred solution, DIEA (8.0mL, 46.1mmol) and 1-methyl-1H-imidazole-4-carbonyl chloride HCL (5.6gm, 30.7mmol) were added under nitrogen at room temperature. After 24 hours, H is used for the reaction₂Quench O and extract with EtOAc. The organic layer was then treated with 10% citric acid solution, H₂O、NaHCO₃And a saline flush. The combined extracts were extracted with anhydrous MgSO₄Dried, filtered and concentrated under reduced pressure to give 6.7gm 6- { [ (1-methyl-1H-imidazole-4-carbonyl) - (3-trifluoromethoxy-benzyl) -amino]-methyl } -3-aza-bicyclo [3.1.0]Hexane-3-carboxylic acid tert-butyl ester 400MHz¹H NMR(CDCl₃)δ7.8(d，J＝1.2Hz，1H)，7.3-7.1(m，5H)，5.4(s，1H)，4.8-4.7(m，1H)，4.2(m，1H)，3.7(s，1H)，3.7(s，3H)，3.4-3.2(m，3H)，1.4(s，9H)，1.3(m，2H)，0.8(m，1H)；MS(M+1)495.3。

The following compounds were prepared using the procedure described in preparation 4.

6- { [ (1-methyl-1H-imidazole-4-carbonyl) - (3-trifluoromethyl-benzyl) -amino]-methyl } -3-aza-bis Cyclo [3.1.0]Hexane-3-carboxylic acid tert-butyl ester

400MHz ¹H NMR(CDCl₃)δ7.6-7.2(m，6H)，5.4(s，1H)，4.9-4.8(m，1H)，4.2(m，1H)，3.7(s，3H)，3.4-3.2(m，7H)，1.4(m，9H)，0.8(m，1H)；LCMS(M+0)479.1。

6- { [ (3-chloro-benzyl) - (1-methyl-1H-imidazole-4-carbonyl) -amino]-methyl } -3-aza-bicyclol [3.1.0]Hexane-3-carboxylic acid tert-butyl ester

400MHz ¹H NMR(CDCl₃)δ7.6(s，1H)，7.4(s，1H)，7.2-7.1(m，4H)，5.4(d，1H)，4.8-4.7(m，1H)，4.2(m，1H)，3.8(s，1H)，3.7(s，3H)，3.5-3.4(m，2H)，3.3-3.2(m，2H)，1.4(s，9H)，1.4-1.3(m，2H)，0.8(m，1H)；MS(M+1)445.3。

6- { [ (4-fluoro-3-trifluoromethyl-benzyl) - (1-methyl-1H-imidazole-4-carbonyl) -amino]-methyl } -3-nitrogen Hetero-bicyclo [3.1.0]Hexane-3-carboxylic acid tert-butyl ester

400MHz ¹H NMR(CDCl₃)δ7.6(s，1H)，7.5(m，2H)，7.3(m，1H)，7.1(t，J＝9.5Hz，1H)，5.4(s，1H)，4.8-4.7(m，1H)，4.2(m，1H)，3.9-3.8(m，1H)，3.7(s，3H)，3.5(m，1H)，3.4-3.2(m，4H)，1.4(m，2H)，1.4(s，9H)，0.8(m，1H)；MS(M+1)497.3。

6- { [ (3-chloro-4-fluoro-benzyl) - (1-methyl-1H-imidazole-4-carbonyl) -amino]-methyl } -3-aza-bis Cyclo [3.1.0]Hexane-3-carboxylic acid tert-butyl ester

400MHz ¹H NMR(CDCl₃)δ7.6(s，1H)；7.3-7.4(m，2H)；7.1-7.2(m，1H)；7.0-7.1(t，J＝8.7Hz，1H)；5.3-5.4(m，1H)；4.6-4.8(m，1H)；4.1-4.2(m，1H)；3.7(m，3H)；3.2-3.5(m，5H)；1.3-1.4(m，11H)；0.8(m，1H)；MS(M+1)463.0。

Example 1

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy -benzyl) -amide hydrochloride

To tert-butyl 6- { [ (1-methyl-1H-imidazole-4-carbonyl) - (3-trifluoromethoxy-benzyl) -amino ] -methyl } -3-aza-bicyclo [3.1.0] hexane-3-carboxylate (7.74gm, 15.65mmol) prepared above was added 5mL of saturated HCl/EtOAc at room temperature. The reaction was stirred at room temperature for 4 hours. The mixture was concentrated under reduced pressure to give 6.63gm of 1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide hydrochloride.

400MHz ¹H NMR(CD₃OD)δ9.0(s，1H)，8.2(brs，1H)，7.5-7.2(m，4H)，5.0，brs，2H)，4.0-3.9(m，4H)，3.6-3.4(m，2H)，3.3(m，3H)，1.8(brs，2H)，1.32(brs，1H)；MS(M+1)395.3。

The following compounds were prepared using the procedure described in example 1.

Example 2

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethyl- Benzyl) -amide hydrochloride

400MHz ¹H NMR(CD₃OD)δ9.0(s，1H)，8.2(brs，1H)，7.6(m，4H)，5.0(brs，2H)，4.0-3.9(m，4H)，3.6(m，2H)，3.3-3.2(m，3H)，1.8(brs，2H)，1.2(brs，1H)。

Example 3

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-chloro-benzyl) -acyl Amine hydrochloride

400MHz ¹H NMR(CD₃OD)δ9.0(s，1H)，8.2(brs，1H)，7.3-7.2(m，4H)，5.0，brs，2H)，4.-3.9(m，4H)，3.56(m，2H)，3.3(m，3H)，1.8(brs，2H)，1.2(brs，1H)；MS(M+1)345.1。

Example 4

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (4-fluoro-3-trifluoromethyl) Yl-benzyl) -amide hydrochloride

400MHz ¹H NMR(CD₃OD)δ9.0(s，1H)，8.2(brs，1H)，7.6(m，2H)，7.4(s，1H)，4.9(brs，2H)，4.0(m，4H)，3.6-3.4(m，2H)，3.3(s，3H)，1.8(brs，2H)，1.4(brs，1H)。

Example 5

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-chloro-4-fluoro-benzyl Acyl) -amidesHydrochloride salt

400MHz 1HNMR(CD₃OD)δ9.1(s，1H)；8.3(brs，1H)；7.5(m，1H)；7.2-7.4(m，2H)；4.8-5.2(m，4H)；3.9-4.1(m，3H)；3.5-3.6(m，2H)；3.2-3.3(m，2H)；1.8(m，3H)；1.4(m，1H)；MS(M+1)363.0。

Example 6

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (4-fluoro-3-isopropoxy) Yl-benzyl) -amides

100MHz ¹³C NMR(CD₃OD)δ19.44，21.26，21.78，35.94，49.72，60.37，72.27，116.33，120.59，124.55，126.54，137.30，146.35，151.91，154.35，158.89，171.74。

Example 7

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-cyclopentyloxy-4- Fluoro-benzyl) -amides

100MHz ¹³C NMR(CD₃OD)δ19.45，21.75，23.71，32.55，33.25，35.80，49.64，51.77，60.36，79.18，81.06，112.50，116.16，118.73，120.05，124.59，126.51，132.29，133.54，137.25，146.44，152.76(d，J＝248)，158.77，171.74。

Example 8

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - [ (3- (2, 2-dimethyl) -propoxy) -4-fluoro-benzyl) -amide

100 MHz ¹³C NMR(CD₃OD)δ19.41，21.74，25.73，31.79，35.80，49.68，51.74，79.03，112.49，114.60，115.85，120.02，124.53，126.51，137.21，148.05，152.20(d，J＝245)，158.85。

Example 9

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-cyclohexyloxy-4- Fluoro-benzyl) -amides

100MHz ¹³C NMR(CD₃OD)δ19.46，21.73，23.31，25.49，31.62，35.79，41.04，49.56，51.63，52.51，77.23，116.52，120.63，124.59，126.51，129.48，137.21，151.02，153.21(d，J＝245)，158.68。

Example 10

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - [ (3- (2, 2, 2-trifluoro-2) -1-trifluoromethyl-ethyl) -benzyl) -amide

400MHz ¹HNMR(CDCl₃)δ7.5(s，1H)；7.2-7.4(m，5H)；5.4(brs，1H)；4.8(brs，1H)；3.9-4.1(m，2H)；3.6(s，3H)；3.3(m，1H)；2.6-3.0(m，4H)；1.2-1.3(m，2H)；0.8-0.9(m，1H)；100MHz ¹³C NMR(CD₃OD)δ17.70，19.01，21.63，23.35，28.55，33.72，47.53，48.24，49.23，50.19，51.74，54.19(h，J＝29)，118.92，121.71，124.54，126.54，126.78，127.34，128.55，129.40，136.85，138.26，139.96，164.28；MS(M+1)461。

Example 11

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - [ (3- (2, 2, 2-trifluoro-2) -ethyl) -benzyl) -amide

400MHz ¹HNMR(CDCl₃)δ7.5(s，1H)；7.1-7.3(m，5H)；5.4(brs，1H)；4.8(brs，1H)；3.9(brs，1H)；3.6(m，3H)；3.2-3.3(m，3H)；2.7-2.8(m，3H)；2.1-2.2(m，1H)；1.4(m，2H)；0.7-0.8(m，1H)；100MHz ¹³C NMR(CD₃OD)δ3.13，17.34，18.69，23.82，33.75，40.26(q，J＝30)，47.64，48.89，49.54，51.82，53.66，121.81，124.57，126.43，127.33，128.97，129.42，130.08，130.46，136.85，138.46，139.3 1，164.29；MS(M+1)393.0。

Example 12

1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopropylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3- Trifluoromethoxy-benzyl) -amides

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] prepared on top at room temperature]To a stirred solution of hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide hydrochloride (0.8gm, 1.9mmol) in 18.5mL of DCE was added cyclopropylformaldehyde (Cyclopropanecarbaldehyde) (0.1mL, 1.6mmol) and NaHB (OAc)₃(0.8gm, 3.7 mmol). The reaction was stirred at room temperature for 16 h by addition of saturated NaHCO₃Quenching the reaction and using CH₂Cl₂And (4) extracting. The combined organic layers were over anhydrous MgSO₄Drying, filtering and concentrating under reduced pressure to give a crude material which is flash chromatographed with 5-30% MeOH/CH₂Cl₂And (5) purifying. The fractions containing the product were collected and concentrated to give 1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopropylmethyl-3-aza-bicyclo [3.1.0]]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide 0.5 gm. 400MHz¹H NMR(CDCl₃)δ7.5(s，1H)，7.3(m，2H)7.2-7.0(m，3H)，5.5(brs，1H)4.8(brs，1H)，4.0(brs，1H)，3.7(s，3H)，3.3(brs，1H)，3.0(m，2H)，2.2(m，4H)，1.5(brs，1H)，1.3(m，2H)，0.8(m，1H)，0.4(m，2H)，0.0(m，2H)；MS(M+1)449.3。

General procedure for the reductive alkylation preparation of Compounds of formula IX

To a stirred solution of 1.0 equivalent of the compound of formula (VIII) in 1, 2-dichloroethane (0.1M) at room temperature were added the appropriately substituted aldehyde or ketone reagent (1.0-1.5 equivalents) and sodium triacetoxyborohydride (2.0 equivalents). Reaction mixtureThe compound was stirred at room temperature for 24 hours. The mixture was then quenched by addition of saturated sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were over anhydrous MgSO₄Dried and concentrated under reduced pressure. If desired, the crude material obtained is purified by flash chromatography with 4% MeOH/CH₂Cl₂And (5) purifying. Fractions containing the product were collected and concentrated to give the desired tertiary amine in 70-95% yield.

The following compounds were prepared using the procedure of example 12 above, starting with the appropriate starting amine of formula (VIII) and the appropriate aldehyde or ketone reagent.

Furthermore, pharmaceutically acceptable salts of the compounds listed below can be prepared as follows. To a stirred solution of a compound of formula (IX) (prepared as described in examples 1 and 12 above, 1.0 equivalent) in a suitable solvent such as ethyl acetate, dioxane, diethyl ether, methyl ethyl ketone, dichloromethane/methanol (1: 1) or methanol (0.1M) was added a suitable acid such as hydrochloric acid, citric acid, trifluoroacetic acid, p-toluenesulfonic acid, methanesulfonic acid or benzenesulfonic acid (2-3 equivalents) in one portion at room temperature. The resulting mixture was stirred at room temperature for 18 hours and then concentrated under reduced pressure to give the desired salt.

Example 13

1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopentylmethyl-3-aza-bicyclo [ 3.1.0)]Hexyl-6-yl methyl Yl) - (3-trifluoromethoxy-benzyl) -amide

400MHz ¹H NMR(CDCl₃)δ7.5(m，1H)，7.3-7.0(m，5H)，5.5(brs，1H)4.8(brs，1H)，4.0(brs，1H)，3.7(s，3H)，3.3(brs，1H)，2.9-2.8(m，2H)，2.19(m，4H)，1.8(brs，1H)，1.6-1.1(m，10H)；MS(M+1)477.3。

Example 14

1-methyl-1H-imidazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (4-trifluoromethoxy-benzyl) -3- Aza-bicyclo [3.1.0]Hex-6-ylmethyl]- - (O) -amides

400MHz ¹H NMR(CDCl₃)δ7.5(s，1H)，7.5-7.0(m，9H)，5.5(brs，1H)4.8(brs，1H)，4.0(brs，1H)，3.7(s，3H)，3.5-3.4(m，2H)，3.3(m，1H)，2.8-2.7(m，2H)，2.2(brs，2H)，1.4(brs，1H)，1.2(brs，2H)；MS(M+1)569.5。

Example 15

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-cyclopropylmethyl-3-aza-bicyclo [ 3.1.0)] Hex-6-ylmethyl) -amide

400MHz ¹H NMR(CDCl₃)δ7.5(m，1H)，7.3-7.2(m，5H)，5.4(brs，1H)4.8(brs，1H)，4.0(brs，1H)，3.7(s，3H)，3.3(brs，1H)，3.0(brs，1H)，2.2(brs，4H)，1.7(brs，2H)，1.4(brs，1H)，1.3(brs，2H)，0.4(m，2H)，0.0(m，2H)；MS(M+1)399.3。

Example 16

methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-cyclopentylmethyl-3-aza-bicyclo [ 3.1.0)]Has already got -6-ylmethyl) -amide

400MHz ¹H NMR(CDCl₃)δ7.6(m，1H)，7.3-7.2(m，5H)，5.4(brs，1H)4.8(brs，1H)，3.9(brs，1H)，3.7(brs，3H)，3.3(m，1H)，2.9(m，2H)，2.2(m，3H)，1.9-1.1(m，13H)；MS(M+1)427.4。

Example 17

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (4-trifluoromethoxy-benzyl) -3-aza-bis Cyclo [3.1.0]Hex-6-ylmethyl]-amides of

400MHz ¹H NMR(CDCl₃)δ7.6(d，1H)，7.5-7.1(m，9H)，5.4(brs，1H)，4.8(brs，1H)，4.0(brs，1H)，3.7(s，3H)，3.5(brs，2H)，3.3(d，1H)，2.8(m，2H)，2.2(m，2H)，1.40(brs，1H)，1.2(brs，2H)；MS(M+1)519.4。

Example 18

1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopropylmethyl) -3-aza-bicyclo [3.1.0]Hexyl-6-yl methyl Yl) - (3-trifluoromethyl-benzyl) -amide

400MHz ¹H NMR(CDCl₃)δ7.6-7.4(m，6H)，5.4(brs，1H)4.8(brs，1H)，3.9-3.7(m，5H)，3.0(m，2H)，2.9(m，2H)，2.4(brs，2H)，1.8(m，2H)，1.4(m，2H)，0.7(m，2H)，0.4-0.3(m，2H)；MS(M+1)433.3。

Example 19

1-methyl-1H-imidazole-4-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (4-fluoro -3-trifluoromethyl-benzyl) -amide

400MHz 1HNMR(CDCl₃)δ7.5-7.6(m，3H)，7.3(s，1H)；7.1(t，J＝9.3，1H)，5.4(brs，1H)，4.8(brs，1H)，4.0(brs，1H)，3.7(s，3H)，3.3(brs，1H)，2.2-3.0(m，4H)，1.0-1.7(m，8H)。

Example 20

1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - (3-methyl-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl) -amide

400MHz 1HNMR(CDCl₃)δ7.5-7.6(m，3H)；7.3(s，1H)；7.1(t，J＝9.3，1H)；5.4(brs，1H)；4.8(brs，1H)；4.0(brs，1H)；3.6-3.7(m，3H)；3.3(brs，1H)；2.8-3.1(brs，2H)；2.3(brs，5H)；1.2-1.4(m，3H)。

Example 21

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl)Yl) - (3-ethyl-3-aza-bicyclo [3.1.0]Hex-6-yl Methyl) -amides

400MHz 1HNMR(CDCl₃)δ7.5(m，1H)；7.1-7.3(m，5H)；54(brs，1H)；4.8(brs，1H)；4.0(brs，1H)；3.7(m，3H)；3.3(brs，1H)；3.0(brs，2H)；2.1-2.4(m，4H)；1.2-1.4(m，3H)；0.9-1.0(m，3H)。

Example 22

1-methyl-1H-imidazole-4-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoro-methyl) Methoxy-benzyl) -amide hydrochloride

400MHz 1HNMR(CD₃OD)δ7.6(m，2H)；7.1-7.4(m，4H)；5.3(brs，1H)；4.8(brs，1H)；3.8(brs，1H)；3.7(brs，3H)；3.3(brs，1H)；2.8(brs，2H)；2.3-2.5(m，4H)；1.3(brs，3H)；1.0(m，3H)。

Example 23

1-methyl-1H-imidazole-4-carboxylic acid (3-methyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoro-methyl) Methoxy-benzyl) -amides

400MHz 1HNMR(CDCl3)δ7.5(m，1H)；7.1-7.3(m，5H)；5.5(brs，1H)；4.8(brs，1H)；4.0(brs，1H)；3.7(brs，3H)；3.3(brs，1H)；2.9(brs，2H)；2.2(brs，5H)；1.3-1.4(m，3H)。

Example 24

1-methyl-1H-imidazole-4-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoro-methyl) Methyl-benzyl) -amides

400MHz ¹HNMR(CDCl₃)δ7.6(m，1H)；7.3-7.5(m，5H)；5.5(brs，1H)；4.9(brs，1H)；4.0(brs，1H)；3.6-3.7(m，3H)；3.3(brs，1H)；3.0(brs，2H)；2.0-2.4(m，4H)；1.2-1.5(m，3H)；1.0(brs，3H)。

Example 25

1-methyl-1H-imidazole-4-carboxylic acid (3-methyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoro-methyl) Methyl-benzyl) -amides

400MHz ¹HNMR(CDCl₃)δ7.3-7.6(m，6H)；5.5(brs，1H)；4.8(brs，1H)；4.0(brs，1H)；3.6-3.7(m，3H)；3.3(brs，1H)；3.0(m，2H)；2.3(m，5H)；1.3-1.7(m，3H)。

Example 26

1-methyl-1H-imidazole-4-carboxylic acid (3, 5-dichloro-benzyl) - (3-methyl-3-aza-bicyclo [ 3.1.0)]Hexane-6- Ylmethyl) -amides

400MHz ¹HNMR(CDCl₃)δ7.6(m，1H)；7.3(brs，1H)；7.1-7.2(m，3H)；5.4(brs，1H)；4.7(brs，1H)；4.0(brs，1H)；3.7(brs，3H)；3.3(brs，1H)；2.9(brs，2H)；2.3(brs，5H)；1.2-1.4(m，3H)。

Example 27

1-methyl-1H-imidazole-4-carboxylic acid (3, 5-dichloro-benzyl) - (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hexane-6- Ylmethyl) -amide hydrochloride

400MHz ¹HNMR(CD₃OD)δ9.0(s，1H)；8.3(brs，1H)7.3-7.4(m，3H)；4.8(brs，2H)；4.0-4.1(m，4H)；3.5-3.6(m，5H)；3.1-3.2(m，2H)；1.8(m，3H)；1.2-1.3(m，3H)。

Example 28

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-4-fluoro-benzyl) - (3-methyl-3-aza-bicyclo [ 3.1.0)]Has already got -6-ylmethyl) -amide

400MHz ¹HNMR(CDCl₃)δ7.52(s，1H)，7.28(m，2H)，7.11(m，1H)，7.00(t，J＝8，1H)，4.67 and 5.355(m，2H)，3.65(s，3H)，3.24 and 3.925(m，2H)，2.86(m，2H)，2.19(s，5H)，1.36(m，1H)，1.26(m，2H)；MS(M+1)377.1.100MHz ¹³C-NMR(CDCl₃，δ)：18.375，19.616，22.763，33.791，41.499，47.025，48.355，49.522，50.112，57.133，116.5785(d，J＝21)，120.929，126.724，127.576，129.789，135.7，136.742，138.432，157.325(d，J＝248)，164.039。

Example 29

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-4-fluoro-benzyl) - (3-ethyl-3-aza-bicyclo [ 3.1.0)]Has already got -6-ylmethyl) -amide

400MHz ¹HNMR(CD₃OD)δ9.0(s，1H)；8.2-8.3(m，1H)7.5(s，1H)；7.3(m，2H)；4.8(brs，2H)；3.8-4.0(m，4H)；3.4-3.6(m，4H)；3.1-3.3(m，2H)；1.6-1.8(m，3H)；1.3(m，3H)。

Example 30

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-methyl-3-aza-bicyclo [ 3.1.0)]Hex-6-yl Methyl) -amides

400MHz ¹HNMR(CDCl₃)δ7.6(s，1H)；7.2-7.3(m，5H)；5.4(brs，1H)；4.8(brs，1H)；4.0(brs，1H)；3.7(s，3H)；3.3(brs，1H)；3.0(brs，2H)；2.2-2.3(m，5H)；1.3-1.5(m，3H)。

Example 31

1-methyl-1H-imidazole-4-carboxylic acid- (3-azetidin-3-yl-3-aza-bicyclo [3.1.0]Hexyl-6-yl methyl Yl) - (3-trifluoromethoxy-benzyl) -amide

100MHz ¹³C-NMR(CDCl₃)δ15.45，19.4，21.79，33.88，42.10，47.56，50.31，50.75，53.10，119.33，119.67，120.23，121.89，126.22，128.62，129.09，130.10，137.13，137.75，141.29，149.63，164.38。

Example 32

1-methyl-1H-imidazole-4-carboxylic acid (2, 4-dichloro-benzyl) - (3-methyl-3-aza-bicyclo [ 3.1.0)]Hexane-6- Ylmethyl) -amides

400MHz ¹HNMR(CDCl3)δ7.6(brs，1H)；7.2(m，3H)；7.1(m，1H)；5.5(brs，1H)；4.8(brs，1H)；4.1(brs，1H)；3.7(brs，3H)；3.3(brs，1H)；2.9(brs，2H)；2.2(brs，5H)；1.3-1.4(m，3H)；MS(M+1)393.0。

Example 33

1-methyl-1H-imidazole-4-carboxylic acid (2, 4-dichloro-benzyl) - (3-7-yl-3-aza-bicyclo [ 3.1.0)]Hexane-6- Ylmethyl) -amides

400MHz ¹HNMR(CDCl₃)δ7.6(brs，1H)；7.2-7.4(m，3 H)；7.1(m，1H)；5.5(brs，1H)；4.8(brs，1H)；4.1(brs，1H)；3.6-3.7(m，3H)；3.3(brs，1H)；2.9-3.0(m，2H)；2.4(m，2H)；2.2(m，2H)；1.3-1.4(m，3H)；0.9-1.0(m，3H)；MS(M+1)407.0。

Example 34

1-methyl-1H-imidazole-4-carboxylic acid (3, 4-dichloro-benzyl) - (3-methyl-3-aza-bicyclo [ 3.1.0)]Hexane-6- Ylmethyl) -amides

400MHz ¹HNMR(CDCl₃)δ7.6(m，1H)；7.3-7.4(m，3H)；7.1(brs，1H)；5.4(brs，1H)；4.7(brs，1H)；4.0(brs，1H)；3.6(brs，3H)；3.3(brs，1H)；3.0(brs，2H)；2.2-2.3(m，5H)；1.2-1.4(m，3H)。

Example 35

1-methyl-1H-imidazole-4-carboxylic acid (3, 4-dichloro-benzyl) - (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hexane-6- Ylmethyl) -amides

400MHz ¹HNMR(CDCl₃)δ7.6(s，1H)；7.3-7.4(m，3H)；7.1(brs，1H)；5.4(brs，1H)；4.7(brs，1H)；4.0(brs，1H)；3.7(s，3H)；3.3(brs，1H)；3.0(brs，2H)；2.2-2.4(m，4H)；1.2-1.4(m，3H)；1.0(brs，3H)。

Example 36

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-methanesulfonyl-azetidin-3-yl) -3-aza-bicyclo [3.1.0] Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide

100MHz ¹³C-NMR(CDCl₃)δ18.42，19.70，21.98，33.84，35.62，47.70，49.72，50.69，51.21，54.75，112.50，1 19.55，120.30，125.98，126.72，129.95，136.82，138.39，149.61，164.17。

Example 37

1-methyl-1H-imidazole-4-carboxylic acid (3-azetidin-3-yl-3-aza-bicyclo [ 3.1.0)]Hexyl-6-yl methyl Yl) - (4-fluoro-3-trifluoromethyl-benzyl) -amide

100MHz ¹³C-NMR(CDCl₃)δ18.30，19.62，22.02，22.09，33.78，47.55，48.73，49.93，50.67，51.28，51.57，53.06，53.45，56.49，57.66，117.01(d，J＝21)，121.40，124.11，126.28，126.32，126.74，133.23，135.19，136.85，138.12，158.93(d，J＝255)，164.02；MS(M+1)452.2。

Example 38

1-methyl-1H-imidazole-4-carboxylic acid (3-azetidin-3-yl-3-aza-bicyclo [ 3.1.0)]Hexyl-6-yl methyl Yl) - (3-chloro-4-fluoro-benzyl) -amides

100MHz ¹³C-NMR(CDCl₃)δ18.29，19.56，21.99，33.83，47.44，48.52，49.69，50.31，50.58，51.29，51.52，56.37，116.59(d，J＝21)，126.62，127.44，129.75，135.85，136.90，138.08，157.29(d，J＝245)，164.10；MS(M+1)418.2。

Example 39

1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - [3- (1-methyl-azetidine-3-) Yl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of

100MHz ¹³C-NMR(CDCl₃)δ18.40，19.65，22.15，33.84，46.09，47.66，48.95，50.70，51.82，52.97，61.05，116.92，117.12，126.33，126.90，133.29，136.79；MS(M+1)466.2。

Example 40

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-4-fluoro-benzyl) - [3- (1-methyl-azetidin-3-yl) -3-aza Hetero-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of

100MHz ¹³C-NMR(CDCl₃)δ18.43，22.11，33.85，45.95，47.55，49.71，50.61，51.84，52.89，61.00，74.97，116.50，116.71，126.82，127.71，129.93，136.85；MS(M+1)464.2。

EXAMPLE 41

1-methyl-1H-imidazole-4-carboxylic acid (3-azetidin-3-yl-3-aza-bicyclo [ 3.1.0)]Hexyl-6-yl methyl Yl) - (3-trifluoromethyl-benzyl) -amide

100MHz ¹³C-NMR(CDCl₃)δ21.84，22.02，25.90，33.88，47.17，50.31，50.79，51.53，52.50，53.19，57.37，124.36，126.69，129.14，131.04，136.84，161.09，164.25；MS(M+1)434.1。

Example 42

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-methyl-azetidin-3-yl) -3-aza-bicyclo [3.1.0]Has already got -6-ylmethyl]- (3-trifluoromethyl-benzyl) -amide

100MHz ¹³C-NMR(CDCl₃)δ18.41，19.72，22.14，33.83，45.86，47.75，49.23，49.90，51.33，51.79，52.82，60.96，124.05，124.40，126.74，129.07，131.01，136.82，164.17；MS(M+1)448.4。

Example 43

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (1-methyl-azetidin-3-yl) -3-aza-bis Cyclo [3.1.0]Hex-6-ylmethyl]-amides of

100MHz ¹³C-NMR(CDCl₃)δ18.43，19.66，22.12，33.82，46.02，47.59，48.97，51.12，51.82，52.89，61.06，126.03，126.67，127.35，127.67，129.86，134.50，136.81，138.55，164.08；MS MS(M+1)414.2。

Example 44

1-methyl-1H-imidazole-4-carboxylic acid (3-methyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - [3- (2, 2, 2-trifluoro-ethyl) -benzyl]-amides of

400MHz ¹HNMR(CDCl₃)δ7.5(s，1H)；7.1-7.3(m，5H)；5.4(brs，1H)；4.8(brs，1H)；3.9(brs，1H)；3.6(s，3H)；3.2-3.3(m，3H)；2.9(brs，2H)；2.2(m，5H)；1.4(m，1H)；1.2-1.3(m，2H)；100MHz ¹³C-NMR(CDCl₃)δ18.47，19.64，22.73，33.74，40.31(q，J＝29)，41.50，46.87，48.76，49.22，50.87，57.17，121.87，124.59，126.38，127.34，128.96，129.40，130.45，136.73，138.60，139.32，164.20；MS(M+1)407.1。

Example 45

1-methyl-1H-imidazole-4-carboxylic acid (3-methyl-3-aza-bicyclo [ 3.1.0)]Hexyl-6-yl methyl -phenyl) - [3- (2, 2, 2-trifluoro-1-trifluoromethyl-ethyl) -benzyl]-amides of

400MHz ¹HNMR(CDCl₃)δ7.5(s，1H)；7.2-7.4(m，5H)；5.4(brs，1H)；4.8(brs，1H)；3.9-4.0(m，2H)；3.6(s，3H)；3.3(brs，1H)；2.8(m，2H)；2.2(m，5H)；1.4(m，1H)；1.2(m，2H)；100MHz ¹³C-NMR(CDCl₃)δ18.44，19.62，22.76，33.72，41.43，47.09，48.85，49.50，50.88，54.37(h，J＝29)，57.09，118.94，121.71，124.51，126.48，126.70，127.33，128.26，129.39，136.73，138.51，139.70，164.22；MS(M+1)475.1。

Example 46

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-hydroxy-cyclohexylmethyl) -3-aza-bicyclo [3.1.0]Hexane-6- Radical methyl]- (3-trifluoromethoxy-benzyl) -amide

Methylene cyclohexane epoxide (methylene cyclohexane epoxide) was added to a 15 mL round bottom flask under nitrogen, followed by ethanol (3.3mL), triethylamine (0.097mL, 0.696 mmo1), and 1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0]]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide hydrochloride (0.100g, 0.232 mmol). The reaction was heated to 60 ℃ and then refluxed for 4.5 hours, then cooled to room temperature. The reaction was then quenched with saturated sodium bicarbonate solution and extracted twice with dichloromethane. The combined organic layers were dried (MgSO)₄) Filtered and concentrated in vacuo to give 0.087g of 1-methyl-1H-imidazole-4-carboxylic acid [3- (1-hydroxy-cyclohexylmethyl) -3-aza-bicyclo [ 3.1.0%]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide. 400MHz¹HNMR(CDCl₃)δ7.6(s，1H)，7.0-7.3(m，5H)，5.4(brs，1H)，4.8(brs，1H)，4.0(brs，1H)，3.7(s，3H)，3.3(brs，1H)，2.9-3.0(m，2H)，2.4-2.5(m，2H)，2.3(m，2H)，1.2-1.8(m，13H)；MW(M+1)507.1。

Other embodiments prepared according to the steps described in example 46 above include:

example 47

1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (2-chloro-phenyl) -2-hydroxy-ethyl]-3-aza-bicyclol [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide

400MHz ¹H NMR(CDCl₃)δ7.6(d，J＝1.24Hz，1H)，7.1-7.4(m，9H)，5.5(brs，1H)，4.8(brs，1H)，4.5(brs，1H)，4.0(brs，1H)，3.7(s，3H)，3.3(brs，1H)，2.8-3.2(m，2H)，2.1-2.6(m，4H)，1.2-1.6(m，3H)；MW(M+1)549.3。

Example 48

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-hydroxy-cyclopentylmethyl) -3-aza-bicyclo [3.1.0]Hexane-6- Radical methyl]- (3-trifluoromethoxy-benzyl) -amide

400MHz ¹H NMR(CDCl₃)δ7.6(d，J＝1.7Hz，1H)，7.3(t，J＝7.9Hz，2H)，7.1-7.2(m，2H)，7.1(d，J＝8.3Hz，1H)，5.5(brs，1H)，4.8(brs，1H)，4.0(brs，1H)，3.7(s，3H)，3.3(brs，2H)，3.0(m，2H)，2.4-2.5(m，4H)，1.7-1.8(m，2H)，1.4-1.6(m，6H)，1.3-1.4(m，3H)；MW(M+1)493.3。

Preparation example 5

2- (6- ((N- (3- (trifluoromethoxy) benzyl) -1-methyl-1H-imidazole-4-carboxamido) methyl) -3-nitrogen Hetero-bicyclo [3.1.0]Hex-3-yl) acetic acid benzyl ester

To a stirred solution of tert-butyl 6- { [ (1-methyl-1H-imidazole-4-carbonyl) - (3-trifluoromethoxy-benzyl) -amino ] -methyl } -3-aza-bicyclo [3.1.0] hexane-3-carboxylate (2.63gm, 5.63mmol) prepared above in 30mL DMF was added potassium carbonate (3.89gm, 28.2mmol), tetraethylammonium chloride (150mg), followed by benzyl 2-bromoacetate (0.88mL, 5.63 mmol). The reaction was stirred at room temperature for 20 hours and quenched with water. The mixture was diluted with ethyl acetate, the layers were separated and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give 2.8gm of crude material. Purification of the crude material by flash chromatography afforded 2.7gm of benzyl 2- (6- ((N- (3- (trifluoromethoxy) benzyl) -1-methyl-1H-imidazole-4-carboxamido) methyl) -3-aza-bicyclo [3.1.0] hex-3-yl) acetate; MS (M +1) 543.3.

Preparation example 6

2- (6- ((N- (3- (trifluoromethyl) benzyl) -1-methyl-1H-imidazole-4-carboxamido) methyl) -3-nitrogen Hetero-bicyclo [3.1.0]Hex-3-yl) acetic acid

To a flask containing 2- (6- ((N- (3- (trifluoromethoxy) benzyl) -1-methyl-1H-imidazole-4-carboxamido) methyl) -3-aza-bicyclo [3.1.0]Hex-3-yl) acetic acid benzyl ester (2.7gm, 5.07mmol)/80mLCH₃A standard bottle of OH (par bottle) was charged with 300mg palladium hydroxide on carbon (20%). The mixture was at 40psi H₂The reaction mixture was hydrogenated at room temperature for 1 hour. The mixture was filtered through celite and CH₃The celite cake was rinsed with OH and the resulting solution was concentrated to give 2.3gm of 2- (6- ((N- (3- (trifluoromethoxy) benzyl) -1-methyl-1H-imidazole-4-carboxamido) methyl) -3-aza-bicyclo [ 3.1.0.3 gm as a yellow solid]Hex-3-yl) acetic acid; 400MHz¹H NMR(CDCl₃)δ7.54(s，1H)，7.23-.733(m，3H)，7.15(s，1H)，7.05(d，J＝7.9Hz，1H)，5.4(brs，2H)，4.81(brs，1H)，3.96(brs，1H)，3.68(s，3H)，3.49(s，2H)，3.28(brs，1H)，3.12(brs，2H)，1.76(brs，1H)，1.66(brs，2H)；MS(M+1)452.1。

General procedure for amide coupling

A solution of 2- (6- ((N- (3- (trifluoromethoxy) benzyl) -1-methyl-1H-imidazole-4-carboxamido) methyl) -3-aza-bicyclo [3.1.0] hex-3-yl) acetic acid (1.0 eq) prepared above in a solution of 1, 2-dichloroethane/triethylamine/dimethylformamide was added to the amine (1.9 eq) followed by HBTU (2.1 eq). The reaction was stirred at room temperature overnight, quenched with 1N NaOH, and extracted with dichloromethane. The combined organic layers were dried and concentrated to give the crude amide, which was further purified by flash chromatography or HPLC.

Alternatively, the amide can be prepared using a parallel library synthesis procedure as described below.

The amine (0.075mmole, 1.875 eq.) was charged to a microtube. 2- (6- ((N- (3- (trifluoromethoxy) benzyl) -1-methyl-1H-imidazole-4-carboxamido) methyl) -3-aza-bicyclo [3.1.0] hex-3-yl) acetic acid was charged to DCE/TEA/DMF (500/14/100) and added as a cloudy suspension (0.04mmol, 18.1mg, 1.0 equiv per 0.614ml DCE/TEA/DMF, 1.0 equiv DIEA). HBTU (31.3mg, 0.0825mmol, 2.06 equiv.) dissolved in 0.2ml DMF was added. Shaken overnight at room temperature. Aliquots were used for LC MS analysis. 1.5ml of 1N NaOH and 2.5ml of DCM were added. Vortex and remove the organic layer and load on SCX SPE (6ml, 1g, silica brand). The extraction was repeated 2 times. The SCX SPE was eluted with 5ml DCM and then 5ml MeOH. Transfer to a tarred collection bottle and elute with 1N TEA/MeOH (7.5 ml). And (5) drying. The TFA salt (15/485 TFA/DCM) was weighed out and prepared. And (5) drying. Purification by HPLC/MS.

Other representative examples prepared according to the above steps and examples include:

examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	49	378.1	379.27	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3, 4-dichloro-benzyl) -amide
50	378.17	379.31	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (2-trifluoromethyl-benzyl) -amide	49	378.1	379.27
50	378.17	379.31		51	396.16	397.43	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-fluoro-5-trifluoromethyl-benzyl) -amide
52	378.17	379.29	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethyl-benzyl) -amide	51	396.16	397.43
52	378.17	379.29		53	378.17	379.29	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethyl-benzyl) -amide
54	378.1	379.27	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (2, 3-dichloro-benzyl) -amide	53	378.17	379.29
54	378.1	379.27		55	378.1	379.25	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (2, 4-dichloro-benzyl) -amide
56	394.16	395.35	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (2-trifluoromethoxy-benzyl) -amide	55	378.1	379.25
56	394.16	395.35		57	396.16	397.37	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (4-fluoro-3-trifluoromethyl-benzyl) -amide
58	396.16	397.37	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (2-fluoro-5-trifluoromethyl-benzyl) -amide	57	396.16	397.37
58	396.16	397.37		59	338.21	339.4	1-methyl-1H-imidazoles-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-phenyl-propyl) -amide
60	402.21	403.4	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (4-phenoxy-benzyl) -amide	59	338.21	339.4
60	402.21	403.4		61	386.21	387.45	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -biphenyl-4-ylmethyl-amide
62	352.23	353.42	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (4-phenyl-butyl) -amide	61	386.21	387.45
62	352.23	353.42		63	391.15	392.45	Pyridine-2-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	64	386.21	387.43	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -biphenyl-3-ylmethyl-amide
65	393.15	394.37	Pyridine-2-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (4-fluoro-3-trifluoromethyl-benzyl) -amide	64	386.21	387.43
65	393.15	394.37		66	393.15	394.39	Pyridine-2-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (5-fluoro-2-trifluoromethyl-benzyl) -amide
67	381.11	381.67	Thiazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethyl-benzyl) -amide	66	393.15	394.39
67	381.11	381.67		68	393.15	394.44	Pyridine-2-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (2-fluoro-5-trifluoromethyl-benzyl) -amide
69	393.15	394.4	Pyridine-2-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-fluoro-5-trifluoromethyl-benzyl) -amide	68	393.15	394.44
69	393.15	394.4		70	397.11	398.37	Thiazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (2-trifluoromethoxy-benzyl) -amide
71	381.11	382.36	Thiazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (2-trifluoromethyl-benzyl) -amide	70	397.11	398.37
71	381.11	382.36		72	397.11	398.38	Thiazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
73	358.16	359.41	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - [2- (4-chloro-phenyl) -ethyl]-amides of	72	397.11	398.38
73	358.16	359.41		74	392.18	393.47	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - [2- (3-trifluoromethyl-phenyl) -ethyl]-amides of
75	349.11	350.44	Thiazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (2, 4-difluoro-benzyl) -amide	74	392.18	393.47
75	349.11	350.44		76	358.16	359.4	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - [2- (3-chloro-phenyl) -ethyl]-amides of
77	450.22	451.16	1-methyl-1H-imidazole-4-carboxylic acid (3-isobutyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	76	358.16	359.4
77	450.22	451.16		78	464.24	465.18	1-methyl-1H-imidazole-4-carboxylic acid [3- (2, 2-dimethyl-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
79	478.22	479.23	1-methyl-1H-imidazole-4-carboxylic acid [3- (tetrahydro-furan-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	78	464.24	465.18

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	80	474.2	475.4	1-methyl-1H-imidazole-4-carboxylic acid [3- (1H-imidazol-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
81	464.24	465.20	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-methyl-butyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	80	474.2	475.4
81	464.24	465.20		82	474.2	475.19	1-methyl-1H-imidazole-4-carboxylic acid [3- (3H-imidazol-4-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
83	464.24	465.20	1-methyl-1H-imidazole-4-carboxylic acid [3- (3-methyl-butyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	82	474.2	475.19
83	464.24	465.20		84	478.26	479.26	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-ethyl-butyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
85	475.18	476.20	1-methyl-1H-imidazole-4-carboxylic acid (3-isoxazol-3-ylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	84	478.26	479.26
85	475.18	476.20		86	478.26	479.28	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-methyl-pentyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
87	488.21	489.24	1-methyl-1H-imidazole-4-carboxylic acid [3- (1-methyl-1H-pyrazol-4-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	86	478.26	479.28
87	488.21	489.24		88	492.27	493.30	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-ethyl-3-methyl-butyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
89	490.26	491.28	1-methyl-1H-imidazole-4-carboxylic acid (3-cyclohexylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	88	492.27	493.30
89	490.26	491.28		90	487.22	488.25	1-methyl-1H-imidazole-4-carboxylic acid [3- (1-methyl-1H-pyrrol-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	91	478.26	479.27	1-methyl-1H-imidazole-4-carboxylic acid [3- (3, 3-dimethyl-butyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
92	498.22	499.25	1-methyl-1H-imidazole-4-carboxylic acid [3- (4-methyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	91	478.26	479.27
92	498.22	499.25		93	492.27	493.30	1-methyl-1H-imidazole-4-carboxylic acid (4-heptyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
94	488.21	489.24	1-methyl-1H-imidazole-4-carboxylic acid [3- (1-methyl-1H-imidazol-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	93	492.27	493.30
94	488.21	489.24		95	498.22	499.24	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-methyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
96	500.24	501.26	1-methyl-1H-imidazole-4-carboxylic acid (3-bicyclo [ 2]2.2.1]Hept-5-en-2-ylmethyl-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	95	498.22	499.24
96	500.24	501.26		97	488.21	489.23	1-methyl-1H-imidazole-4-carboxylic acid [3- (5-methyl-3H-imidazol-4-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl [ - (3-trifluoromethoxy-benzyl) -amide
98	512.24	513.24	1-methyl-1H-imidazole-4-carboxylic acid [3- (2, 4-dimethyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	97	488.21	489.23
98	512.24	513.24		99	498.22	499.25	1-methyl-1H-imidazole-4-carboxylic acid [3- (3-methyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
100	502.23	503.25	1-methyl-1H-imidazole-4-carboxylic acid [3- (1, 5-dimethyl-1H-pyrazol-4-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	99	498.22	499.25
100	502.23	503.25		101	509.2	510.21	1-methyl-1H-imidazole-4-carboxylic acid [3- (4-cyano-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	102	508.23	509.24	2-methyl-3- (6- { [ (1-methyl-1H-imidazole-4-carbonyl) - (3-trifluoromethoxy-benzyl) -amino]-methyl } -3-aza-bicyclo [3.1.0]Hex-3-yl) -propionic acid ethyl ester
103	498.22	499.24	1-methyl-1H-imidazole-4-carboxylic acid (3-phenethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	102	508.23	509.24
103	498.22	499.24		104	502.23	503.25	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-ethyl-3H-imidazol-4 ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
105	512.24	513.25	1-methyl-1H-imidazole-4-carboxylic acid [3- (4-ethyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	104	502.23	503.25
105	512.24	513.25		106	501.2	502.21	1-methyl-1H-imidazole-4-carboxylic acid [3- (6-oxo-1, 6-dihydro-pyridin-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
107	502.23	503.24	1-methyl-1H-imidazole-4-carboxylic acid [3- (2, 5-dimethyl-2H-pyrazol-3-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	106	501.2	502.21
107	502.23	503.24		108	512.24	513.25	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-p-tolyl-ethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
109	516.25	517.25	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-ethyl-5-methyl-3H-imidazol-4 ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	108	512.24	513.25
109	516.25	517.25		110	514.22	515.22	1-methyl-1H-imidazole-4-carboxylic acid [3- (4-methoxy-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
111	506.29	507.31	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-ethyl-hexyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	110	514.22	515.22
111	506.29	507.31		112	516.25	517.25	1-methyl-1H-imidazole-4-carboxylic acid [3- (1-ethyl-3-methyl-1H-pyrazol-4-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	113	518.21	519.21	1-methyl-1H-imidazole-4-carboxylic acid [3- (5-methoxymethyl-furan-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
114	512.24	513.24	1-methyl-1H-imidazole-4-carboxylic acid [3- (3-phenyl-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	113	518.21	519.21
114	512.24	513.24		115	516.21	517.21	1-methyl-1H-imidazole-4-carboxylic acid [3- (3-fluoro-4-methyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
116	518.17	519.21	1-methyl-1H-imidazole-4-carboxylic acid [3- (4-chloro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxybenzyl) -amides	115	516.21	517.21
116	518.17	519.21		117	516.25	517.26	1-methyl-1H-imidazole-4-carboxylic acid [3- (1-ethyl-5-methyl-1H-pyrazol-4-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
118	520.19	521.19	1-methyl-1H-imidazole-4-carboxylic acid [3- (2, 5-difluoro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	117	516.25	517.26
118	520.19	521.19		119	522.18	523.18	1-methyl-1H-imidazole-4-carboxylic acid [3- (4-chloro-1-methyl-1H-pyrazol-3-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
120	519.16	520.17	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-chloro-pyridin-3-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	119	522.18	523.18
120	519.16	520.17		121	524.21	525.22	1-methyl-1H-imidazole-4-carboxylic acid [3- (1H-benzimidazol-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
122	520.19	521.19	1-methyl-1H-imidazole-4-carboxylic acid [3- (3, 5-difluoro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	121	524.21	525.22
122	520.19	521.19		123	523.22	524.22	1-methyl-1H-imidazole-4-carboxylic acid [3- (1H-indol-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	124	525.12	526.13	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-chloro-thiazol-5-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
125	520.19	521.19	1-methyl-1H-imidazole-4-carboxylic acid [3- (2, 3-difluoro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	124	525.12	526.13
125	520.19	521.19		126	523.22	524.22	1-methyl-1H-imidazole-4-carboxylic acid [3- (1H-indol-5-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
127	520.3	521.30	1-methyl-1H-imidazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (3, 5, 5-trimethyl-hexyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of	126	523.22	524.22
127	520.3	521.30		128	520.19	521.20	1-methyl-1H-imidazole-4-carboxylic acid [3- (2, 4-difluoro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
129	526.26	527.25	1-methyl-1H-imidazole-4-carboxylic acid [3- (4-isopropyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	128	520.19	521.20
129	526.26	527.25		130	528.2	529.20	1-methyl-1H-imidazole-4-carboxylic acid (3-benzo [1, 3]]Dioxolen-5-ylmethyl-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
131	550.23	551.24	1-methyl-1H-imidazole-4-carboxylic acid [3- (1-pyridin-2-yl-1H-pyrrol-2-yl)Methyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	130	528.2	529.20
131	550.23	551.24		132	534.22	535.23	1-methyl-1H-imidazole-4-carboxylic acid (3-naphthalen-2-ylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
133	528.2	529.20	1-methyl-1H-imidazole-4-carboxylic acid (3-benzo [1, 3]]Dioxolen-4-ylmethyl-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	132	534.22	535.23
133	528.2	529.20		134	551.23	552.24	1-methyl-1H-imidazole-4-carboxylic acid [3- (1-pyrimidin-2-yl-1H-pyrrol-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	135	534.22	535.23	1-methyl-1H-imidazole-4-carboxylic acid (3-naphthalen-1-ylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
136	530.25	531.26	1-methyl-1H-imidazole-4-carboxylic acid {3- [3- (5-methyl-furan-2-yl) -butyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide	135	534.22	535.23
136	530.25	531.26		137	528.27	529.28	1-methyl-1H-imidazole-4-carboxylic acid [3- (6, 6-dimethyl-bicyclo [ 3.1.1)]Hept-2-en-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
138	541.18	542.19	1-methyl-1H-imidazole-4-carboxylic acid (3-benzothiazol-2-ylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	137	528.27	529.28
138	541.18	542.19		139	550.2	551.22	1-methyl-1H-imidazole-4-carboxylic acid [3- (4-difluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylMethyl radical]- (3-trifluoromethoxy-benzyl) -amide
140	552.2	553.22	1-methyl-1H-imidazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (4-trifluoromethyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of	139	550.2	551.22
140	552.2	553.22		141	560.24	561.26	1-methyl-1H-imidazole-4-carboxylic acid (3-biphenyl-4-ylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
142	568.19	569.22	1-methyl-1H-imidazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (3-trifluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of	141	560.24	561.26
142	568.19	569.22		143	526.26	527.26	1-methyl-1H-imidazole-4-carboxylic acid [3- (3-phenyl-butyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
144	577.23	578.22	1-methyl-1H-imidazole-4-carboxylic acid [3- (6-phenoxy-pyridin-3-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	143	526.26	527.26
144	577.23	578.22		145	576.23	577.23	1-methyl-1H-imidazole-4-carboxylic acid [3- (4-phenoxy-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide;

examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	146	568.19	569.21	1-methyl-1H-imidazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (2-trifluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of
147	502.2	503.24	1-methyl-1H-imidazole-4-carboxylic acid [3- (4-fluoro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	146	568.19	569.21
147	502.2	503.24		148	450.2	451.2	1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopropylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (4-fluoro-3-trifluoromethyl-benzyl) -amide
149	478.24	479.2	1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopentylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (4-fluoro-3-trifluoromethyl-benzyl) -amide	148	450.2	451.2
149	478.24	479.2		150	570.19	571.2	1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - [3- (4-trifluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of
151	508.25	509.2	1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - [3- (1-hydroxy-cyclohexylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of	150	570.19	571.2
151	508.25	509.2		152	578.23	579.2	1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - [3- (4-phenoxy-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of
153	501.17	502.3	Thiazole-4-carboxylic acid (3-phenethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	152	578.23	579.2
153	501.17	502.3		154	451.15	452.3	Thiazole-4-carboxylic acid (3-cyclopropylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
155	479.19	480.3	Thiazole-4-carboxylic acid (3-cyclopentylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	154	451.15	452.3
155	479.19	480.3		156	521.12	521.89	Thiazole-4-carboxylic acid [3- (4-chloro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
157	505.14	506.3	Thiazole-4-carboxylic acid [3- (4-fluoro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	156	521.12	521.89
157	505.14	506.3		158	523.24	524.4	1-methyl-1H-imidazole-4-carboxylic acid (3- { [ ethyl- (2-hydroxy-ethyl) -carbamoyl]-methyl } -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	159	521.26	522.4	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (sec-butyl-methyl-carbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide
160	531.22	531.8	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (1-methyl-1H-pyrazol-3-ylcarbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide	159	521.26	522.4
160	531.22	531.8		161	491.21	492.4	1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopropyl)Aminoformylmethyl-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
162	434.19	435.1	1H-imidazole-4-carboxylic acid (3-cyclopropylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	161	491.21	492.4
162	434.19	435.1		163	380.15	381.1	1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
164	505.23	506.41	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (cyclopropylmethyl-carbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide	163	380.15	381.1
164	505.23	506.41		165	507.25	508.42	1-methyl-1H-imidazole-4-carboxylic acid [3- (tert-butylcarbamoyl-methyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
166	505.23	506.41	1-methyl-1H-imidazole-4-carboxylic acid (3-cyclobutylcarbamoylmethyl-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	165	507.25	508.42
166	505.23	506.41		167	509.22	510.4	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (2-methoxy-ethylcarbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide
168	523.24	524.42	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (2-methoxy-1-methyl-ethylcarbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]} - (3-trifluoromethoxy-benzyl) -amide	167	509.22	510.4
168	523.24	524.42		169	519.25	520.42	1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopentylcarbamoylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
170	509.22	510.4	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (2-hydroxy-propylcarbamoyl } -methyl)]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide	169	519.25	520.42

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	171	527.21	528.38	1-methyl-1H-imidazole-4-carboxylic acid (3-phenylcarbamoylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
172	517.2	518.38	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (1H-imidazol-2-ylcarbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide	171	527.21	528.38
172	517.2	518.38		173	493.23	494.41	1-methyl-1H-imidazole-4-carboxylic acid [3- (isopropylcarbamoyl-methyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
174	521.26	522.44	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (2, 2-dimethyl-propylcarbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;	173	493.23	494.41
174	521.26	522.44		175	528.21	529.38	1-methyl-1H-imidazole-4-carboxylic acid [3- (pyridin-3-ylcarbamoylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
176	570.26	571.42	1-methyl-1H-imidazole-4-carboxylic acid (3- { [ methyl- (3-methyl-pyridin-2-ylmethyl) -carbamoyl]-methyl } -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	175	528.21	529.38
176	570.26	571.42		177	523.24	524.42	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (2-hydroxy-1, 1-dimethyl-ethylcarbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide
178	528.21	529.38	1-methyl-1H-imidazole-4-carboxylic acid [3- (pyridin-2-ylcarbamoylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-3-trifluoromethoxy-benzyl) -amide	177	523.24	524.42
178	528.21	529.38		179	531.22	532.39	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (2-methyl-2H-pyrazol-3-ylcarbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide
180	533.19	534.36	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (2, 2, 2-trifluoro-ethylcarbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide	179	531.22	532.39
180	533.19	534.36		181	531.21	532.38	1-methyl-1H-imidazole-4-carboxylic acid (3- { [ (furan-2-ylmethyl) -carbamoyl]-methyl } -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	182	479.21	480.4	1-methyl-1H-imidazole-4-carboxylic acid (3-dimethylcarbamoylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amides of
183	532.22	533.39	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (1-methyl-1H- [1, 2, 4]]Triazol-3-ylcarbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide	182	479.21	480.4
183	532.22	533.39		184	533.26	534.44	1-methyl-1H-imidazole-4-carboxylic acid (3-cyclohexylcarbamoylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
185	505.23	506.41	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-oxo-2-pyrrolidin-1-yl-ethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	184	533.26	534.44
185	505.23	506.41		186	519.25	520.42	1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (2-methyl-pyrrolidin-1-yl) -2-oxo-ethyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide
187	519.25	520.43	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-oxo-2-piperidin-1-yl-ethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy)Yl-benzyl) -amides	186	519.25	520.42
187	519.25	520.43		188	519.25	520.42	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (cyclopropylmethyl-methyl-carbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide
189	521.22	522.4	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-morpholin-4-yl-2-oxo-ethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	188	519.25	520.42
189	521.22	522.4		190	521.22	522.4	1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (3-hydroxy-pyrrolidin-1-yl) -2-oxo-ethyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide
191	521.22	522.4	1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (3-hydroxy-pyrrolidin-1-yl) -2-oxo-ethyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide	190	521.22	522.4
191	521.22	522.4		192	521.22	522.4	1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (3-hydroxy-pyrrolidin-1-yl) -2-oxo-ethyl]-3-aza-bicyclo [3.1.0]Hexyl-6-yl methylAryl } - (3-trifluoromethoxy-benzyl) -amide

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	193	521.26	522.44	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (ethyl-isopropyl-carbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide
194	522.22	523.4	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (carbamoylmethyl-methyl-carbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide	193	521.26	522.44
194	522.22	523.4		195	533.26	534.44	1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (3-methyl-piperidin-1-yl) -2-oxo-ethyl]-3-nitrogenHetero-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide
196	533.26	534.44	1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (4-methyl-piperidin-1-yl) -2-oxo-ethyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide	195	533.26	534.44
196	533.26	534.44		197	523.19	524.36	1-methyl-1H-imidazole-4-carboxylic acid {3- (2-oxo-2-thiazolidin-3-yl-ethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
198	535.24	536.41	1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (3-hydroxymethyl-pyrrolidin-1-yl) -2-oxo-ethyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide	197	523.19	524.36
198	535.24	536.41		199	535.24	536.42	1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (2-hydroxymethyl-pyrrolidin-1-yl) -2-oxo-ethyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide
200	535.24	536.41	1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (3-hydroxy-piperidin-1-yl) -2-oxo-ethaneBase of]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide	199	535.24	536.42
200	535.24	536.41		201	537.2	537.91	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-oxo-2-thiomorpholin-4-yl-ethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
202	549.26	549.98	1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (2, 6-dimethyl-morpholin-4-yl) -2-oxo-ethyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide	201	537.2	537.91
202	549.26	549.98		203	561.2	561.9	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (methyl-thiophen-2-ylmethyl-carbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide

Examples	MWCalc	Mass spectrum data (M +1)	IUPAC name
Examples	MWCalc	Mass spectrum data (M +1)	IUPAC name	204	545.22	545.94	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (furan-2-ylmethyl-methyl-carbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide
205	555.25	555.98	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (benzyl-methyl-carbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide	204	545.22	545.94
205	555.25	555.98		206	553.23	553.93	1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (1, 3-dihydro-isoindol-2-yl) -2-oxo-ethyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide
207	541.21	541.91	1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (3, 4-difluoro-pyrrolidin-1-yl) -2-oxo-ethyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide	206	553.23	553.93
207	541.21	541.91		208	547.2	547.89	1-methyl-1H-imidazole-4-carboxylic acid (3- { [ methyl- (2, 2, 2-trifluoro-ethyl) -carbamoyl]-methyl } -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
209	561.2	561.91	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (methyl-thiophen-3-ylmethyl-carbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide	208	547.2	547.89
209	561.2	561.91		210	569.26	569.99	1-methyl-1H-imidazole-4-carboxylic acid {3- [ (methyl-phenethyl-carbamoyl) -methyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide
211	570.26	570.95	1-methyl-1H-imidazole-4-carboxylic acid (3- { [ methyl- (1-pyridin-4-yl-ethyl) -carbamoyl]-methyl } -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	210	569.26	569.99
211	570.26	570.95		212	581.26	582.01	1-methyl-1H-imidazole-4-carboxylic acid {3- [ 2-oxo-2- (3-phenyl-pyrrolidin-1-yl) -ethyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide
213	571.21	571.92	1-methyl-1H-imidazole-4-carboxylic acid (3- { [ (2-methanesulfonyl-ethyl) -methyl-carbamoyl]-methyl } -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	212	581.26	582.01
213	571.21	571.92		214	582.26	582.99	1-methyl-1H-imidazole-4-carboxylic acid {3- [ 2-oxo-2- (2-pyridin-4-yl-pyrrolidin-1-yl) -ethyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	215	542.23	543.2	1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - [3- (2-hydroxy-indan-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of
216	579.23	580.2	1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - [3- (6-phenoxy-pyridin-3-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of	215	542.23	543.2
216	579.23	580.2		217	501.17	502.12	Thiazole-4-carboxylic acid [3- (3-methyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
218	505.14	505.91	Thiazole-4-carboxylic acid [3- (2-fluoro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	217	501.17	502.12
218	505.14	505.91		219	517.16	518.16	Thiazole-4-carboxylic acid [3- (4-methoxy-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
220	493.2	494.10	Thiazole-4-carboxylic acid (3-cyclohexylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	219	517.16	518.16
220	493.2	494.10		221	505.14	506.05	Thiazole-4-carboxylic acid [3- (3-fluoro-benzyl)Yl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
222	501.17	502.07	Thiazole-4-carboxylic acid [3- (2-methyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	221	505.14	506.05
222	501.17	502.07		223	579.18	580.07	Thiazole-4-carboxylic acid [3- (4-phenoxy-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
224	515.19	515.97	Thiazole-4-carboxylic acid [3- (2-phenyl-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	223	579.18	580.07
224	515.19	515.97		225	512.15	512.93	Thiazole-4-carboxylic acid [3- (4-cyano-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
226	563.19	563.99	Thiazole-4-carboxylic acid (3-biphenyl-4-ylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	225	512.15	512.93
226	563.19	563.99		227	512.15	512.84	Thiazole-4-carboxylic acid [3- (3-cyano-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
228	555.14	556.03	Thiazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (4-trifluoromethyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of	227	512.15	512.84
228	555.14	556.03		229	515.19	516.08	Thiazole-4-carboxylic acid [3- (3, 5-dimethyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
230	521.12	521.91	Thiazole-4-carboxylic acid [3- (3-chloro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	229	515.19	516.08

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	231	515.19	516.10	Thiazole-4-carboxylic acid [3- (2, 4-dimethyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
232	571.14	572.00	Thiazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (3-trifluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of	231	515.19	516.10
232	571.14	572.00		233	515.19	516.08	Thiazole-4-carboxylic acid [3- (4-ethyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
234	571.14	572.04	Thiazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (4-trifluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of	233	515.19	516.08
234	571.14	572.04		235	491.16	491.99	Thiazole-4-carboxylic acid [3- (1-methyl)-1H-imidazol-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
236	521.16	522.18	Thiazole-4-carboxylic acid [3- (5-methoxymethyl-furan-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	235	491.16	491.99
236	521.16	522.18		237	504.14	504.91	Thiazole-4-carboxylic acid [3- (6-oxo-1, 6-dihydro-pyridin-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
238	519.19	519.99	Thiazole-4-carboxylic acid [3- (1-ethyl-3-methyl-1H-pyrazol-4-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	237	504.14	504.91
238	519.19	519.99		239	490.17	490.97	Thiazole-4-carboxylic acid [3- (1-methyl-1H-pyrrol-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
240	571.14	571.76	Thiazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (2-trifluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of	239	490.17	490.97
240	571.14	571.76		241	477.13	477.98	Thiazole-4-carboxylic acid (3-furan-3-ylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
242	505.18	506.06	Thiazole-4-carboxylic acid [3- (1, 5-dimethyl-1H-pyrazol-4-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	241	477.13	477.98

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	243	477.14	477.85	Thiazole-4-carboxylic acid [3- (1H-imidazol-4-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
244	476.15	476.95	Thiazole-4-carboxylic acid [3- (1H-pyrrol-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	243	477.14	477.85
244	476.15	476.95		245	515.19	516.10	Thiazole-4-carboxylic acid [3- (3-phenyl-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
246	491.16	492.00	Thiazole-4-carboxylic acid [3- (1-methyl-1H-pyrazol-4-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	245	515.19	516.10
246	491.16	492.00		247	519.16	520.18	Thiazole-4-carboxylic acid [3- (4-fluoro-3-methyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
248	491.16	491.84	Thiazole-4-carboxylic acid [3- (5-methyl-3H-imidazol-4-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	247	519.16	520.18
248	491.16	491.84		249	477.13	477.90	Thiazole-4-carboxylic acid (3-furan-2-ylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
250	511.18	512.14	(6- { [ (thiazole-4-carbonyl) - (3-trifluoromethoxy-benzyl) -amino]-methyl) -3-aza-bicyclo [3.1.0]Hex-3-yl) -acetic acid butyl ester	249	477.13	477.90
250	511.18	512.14		251	519.16	520.08	Thiazole-4-carboxylic acid [3- (3-fluoro-4-methyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
252	505.18	505.96	Thiazole-4-carboxylic acid [3- (2-ethyl-3H-imidazol-4-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	251	519.16	520.08
252	505.18	505.96		253	519.19	520.03	Thiazole-4-carboxylic acid [3- (2-ethyl-5-methyl-3H-imidazol-4-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
254	481.16	482.02	Thiazoles-4-carboxylic acid [3- (tetrahydro-furan-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	253	519.19	520.03
254	481.16	482.02		255	515.19	516.08	Thiazole-4-carboxylic acid [3- (2-p-tolyl-ethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	256	519.19	520.08	Thiazole-4-carboxylic acid [3- (1-ethyl-5-methyl-1H-pyrazol-4-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
257	522.11	522.87	Thiazole-4-carboxylic acid [3- (2-chloro-pyridin-3-ylmethyl)) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	256	519.19	520.08
257	522.11	522.87		258	478.13	479.04	Thiazole-4-carboxylic acid (3-isoxazol-3-ylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
259	526.17	527.01	Thiazole-4-carboxylic acid [3- (1H-indol-3-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	258	478.13	479.04
259	526.17	527.01		260	511.18	511.90	2-methyl-3- (6- { [ (thiazole-4-carbonyl) - (3-trifluoromethoxy-benzyl) -amino]-methyl) -3-aza-bicyclo [3.1.0]Hex-3-ylmethyl) -propionic acid ethyl ester
261	491.16	492.00	Thiazole-4-carboxylic acid [3- (5-methyl-2H-pyrazol-3-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	260	511.18	511.90
261	491.16	492.00		262	559.21	560.09	Thiazole-4-carboxylic acid [3- (4-butoxy-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
263	531.14	532.01	Thiazole-4-carboxylic acid (3-benzo [1, 3]]Dioxolen-5-ylmethyl-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	262	559.21	560.09
263	531.14	532.01		264	531.18	531.93	Thiazole-4-carboxylic acid [3- (4-ethoxy-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
265	529.2	530.11	Thiazole-4-carboxylic acid [3- (4-isopropyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	264	531.18	531.93
265	529.2	530.11		266	501.17	501.91	Thiazole-4-carboxylic acid [3- (4-methyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
267	537.17	538.11	Thiazole-4-carboxylic acid (3-naphthalen-2-ylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	266	501.17	501.91
267	537.17	538.11		268	531.14	531.92	Thiazole-4-carboxylic acid (3-benzo [1, 3]]Dioxolen-4-ylmethyl-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	269	523.14	524.15	Thiazole-4-carboxylic acid [3- (2, 3-difluoro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
270	523.14	523.90	Thiazole-4-carboxylic acid [3- (2, 5-difluoro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	269	523.14	524.15
270	523.14	523.90		271	538.17	539.06	Thiazole-4-carboxylic acid (3-quinolin-7-ylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
272	531.18	531.94	Thiazole-4-carboxylic acid [3- (4-methoxy-3-methyl-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	271	538.17	539.06
272	531.18	531.94		273	523.14	524.02	Thiazole-4-carboxylic acid [3- (2, 4-difluoro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
274	533.2	533.96	Thiazole-4-carboxylic acid {3- [3- (5-methyl-furan-2-yl) -butyl]-3-aza-bicyclo [3.1.0]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	273	523.14	524.02
274	533.2	533.96		275	554.17	554.90	Thiazole-4-carboxylic acid [3- (1-pyrimidin-2-yl-1H-pyrrol-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
276	523.14	524.09	Thiazole-4-carboxylic acid [3- (3, 5-difluoro-benzyl) -3-aza-bicyclo [3.1.0]Hexyl-6-yl methylBase of]- (3-trifluoromethoxy-benzyl) -amide	275	554.17	554.90
276	523.14	524.09		277	553.15	554.09	Thiazole-4-carboxylic acid [3- (4-difluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
278	538.17	539.05	Thiazole-4-carboxylic acid (3-quinolin-8-ylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	277	553.15	554.09
278	538.17	539.05		279	533.21	534.02	Thiazole-4-carboxylic acid [3- (2-butyl-1H-imidazol-4-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
280	526.17	526.93	Thiazole-4-carboxylic acid [3- (1H-indol-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	279	533.21	534.02
280	526.17	526.93		281	530.14	530.96	Thiazole-4-carboxylic acid [3- (3-cyano-4-fluoro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	282	526.17	526.90	Thiazole-4-carboxylic acid [3- (1H-indol-5-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
283	535.16	536.09	Thiazole-4-carboxylic acid [3- (2-fluoro-4-methoxy-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	282	526.17	526.90
283	535.16	536.09		284	527.16	527.99	Thiazole-4-carboxylic acid [3- (1H-benzimidazol-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
285	528.07	528.79	Thiazole-4-carboxylic acid [3- (2-chloro-thiazol-5-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	284	527.16	527.99
285	528.07	528.79		286	525.12	526.02	Thiazole-4-carboxylic acid [3- (4-chloro-1-methyl-1H-pyrazol-3-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
287	540.23	541.2	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-hydroxy-indan-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	286	525.12	526.02
287	540.23	541.2		288	456.23	457.2/459.2	1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (1-hydroxy-cyclohexylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of
289	490.21	491.3/493.3	1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (2-hydroxy-indan-2-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of	288	456.23	457.2/459.2
289	490.21	491.3/493.3		290	490.26	491.1	1-methyl-1H-imidazole-4-carboxylic acid [3- (1-hydroxy-cyclohexylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethyl-benzyl) -amide
291	476.24	477.2	1-methyl-1H-imidazole-4-carboxylic acid [3- (1-hydroxy-cyclopentylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethyl-benzyl) -amide	290	490.26	491.1
291	476.24	477.2		292	460.24	461.1	1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopentylmethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethyl-benzyl) -amide

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	293	370.27	371.2	1-methyl-1H-imidazole-4-carboxylic acid cyclohexylmethyl- (3-cyclopropylmethyl-3-aza-bicyclo [ 3.1.0%]Hex-6-ylmethyl) -amide
294	466.22	467.0	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-hydroxy-2-methyl-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	293	370.27	371.2
294	466.22	467.0		295	490.18	491.0	1-methyl-1H-imidazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of
298	462.22	463.1	1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopentyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	295	490.18	491.0
298	462.22	463.1		297	448.21	449.0	1-methyl-1H-imidazole-4-carboxylic acid (3-cyclobutyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
298	440.23	442.1	1-methyl-1H-imidazole-4-carboxylic acid [3- (4-chloro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-cyclohexylmethyl-amide	297	448.21	449.0
298	440.23	442.1		299	478.22	479.0	1-methyl-1H-imidazole-4-carboxylic acid [3- (2-hydroxy-cyclopentyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
300	436.21	437.08	1, 5-dimethyl-1H-pyrazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	299	478.22	479.0
300	436.21	437.08		301	423.18	424.08	5-methyl-isoxazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
302	493.06	493.89	4, 5-dichloro-isothiazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	301	423.18	424.08
302	493.06	493.89		303	451.21	452.07	5-propyl-isoxazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
304	389.16	390	Thiazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (4-fluoro-3-isopropoxy-benzyl) -amide	303	451.21	452.07
304	389.16	390		305	415.17	416.0	Thiazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-cyclopentyloxy-4-fluoro-benzyl) -amide
306	417.19	418.0	Thiazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - [3- (2, 2-dimethyl-propoxy) -4-fluoro-benzyl]-amides of	305	415.17	416.0
306	417.19	418.0		307	429.19	430.0	Thiazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-cyclohexyloxy-4-fluoro-benzyl) -amide

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	308	378.1	379	1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3, 5-dichloro-benzyl) -amide
309	436.21	437.1	1-methyl-1H-imidazole-4-carboxylic acid (3-isopropyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	308	378.1	379
309	436.21	437.1		310	469.2	470.2	Quinoline-2-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
311	419.18	420.24	Pyridine-2-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	310	469.2	470.2
311	419.18	420.24		312	423.18	424.25	5-methyl-isoxazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
313	437.19	438.20	5-Ethyl-isoxazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	312	423.18	424.25
313	437.19	438.20		314	469.2	470.23	Quinaline-4-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
315	448.21	449.21	5-cyclopropyl-2H-pyrazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	314	469.2	470.23
315	448.21	449.21		316	436.21	437.26	1, 5-dimethyl-1H-pyrazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
317	450.22	451.26	2-Ethyl-5-methyl-2H-pyrazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	316	436.21	437.26
317	450.22	451.26		318	422.19	423.21	4-methyl-1H-imidazole-2-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
319	451.21	452.23	5-propyl-isoxazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	318	422.19	423.21
319	451.21	452.23		320	450.22	451.24	5-isopropyl-2H-pyrazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
321	422.19	423.21	1-methyl-1H-pyrazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	320	450.22	451.24
321	422.19	423.21		322	450.22	451.24	5-Ethyl-2-methyl-2H-pyrazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	323	467.19	468.21	2-isopropyl-thiazole-4-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
324	422.19	423.21	1-methyl-1H-imidazole-4-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	323	467.19	468.21
324	422.19	423.21		325	425.14	426.18	Thiazole-4-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
326	453.14	454.16	5-chloro-pyridine-2-carboxylic acid (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide	325	425.14	426.18
326	453.14	454.16		327	386.23	386.81	1-methyl-1H-imidazole-4-carboxylic acid pentyl- [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of
328	386.23	386.94	1-methyl-1H-imidazole-4-carboxylic acid (2-methyl-butyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of	327	386.23	386.81
328	386.23	386.94		329	400.24	401.20	1-methyl-1H-imidazole-4-carboxylic acid (2-ethyl-butyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of
330	370.2	371.13	1-methyl-1H-imidazole-4-carboxylic acid cyclopropylmethyl- [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of	329	400.24	401.20
330	370.2	371.13		331	414.26	415.29	1-methyl-1H-imidazole-4-carboxylic acid heptyl- [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of
332	372.21	373.22	1-methyl-1H-imidazole-4-carboxylic acid butyl- [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of	331	414.26	415.29
332	372.21	373.22		333	412.24	413.22	1-methyl-1H-imidazole-4-carboxylic acid cyclohexylmethyl- [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of
334	414.22	415.20	1-methyl-1H-imidazole-4-carboxylic acid [3- (4-chloro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (2-methyl-butyl) -amide	333	412.24	413.22
334	414.22	415.20		335	426.26	427.21	1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopentyl-propyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of
336	414.22	415.19	1-methyl-1H-imidazole-4-carboxylic acid [3- (4-chloro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-pentyl-amides	335	426.26	427.21
336	414.22	415.19		337	400.2	401.21	1-methyl-1H-imidazole-4-carboxylic acid butyl- [3- (4-chloro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	338	398.19	399.14	1-methyl-1H-imidazole-4-carboxylic acid [3- (4-chloro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-cyclopropylmethyl-amide
339	428.23	429.28	1-methyl-1H-imidazole-4-carboxylic acid [3- (4-chloro-benzyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (2-ethyl-butyl) -amide	338	398.19	399.14
339	428.23	429.28		340	440.16	441.1	1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of
341	428.2	429.1	1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (tetrahydro-pyran-4-yl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of	340	440.16	441.1
341	428.2	429.1		342	492.18	493.1	1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of
343	508.23	509.2	1-methyl-1H-imidazole-4-carboxylic acid [3- (4-hydroxy-tetrahydro-pyran-4-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	342	492.18	493.1
343	508.23	509.2		344	458.21	459.2	1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (4-hydroxy-tetrahydro-pyran-4-ylmethyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of
345	478.22	479.2	1-methyl-1H-imidazole-4-carboxylic acid [3- (tetrahydro-pyran-4-yl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	344	458.21	459.2
345	478.22	479.2		346	480.21	481.2	1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - [3- (tetrahydro-pyran-4-yl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of
347	330.24	331.2	1-methyl-1H-imidazole-4-carboxylic acid cyclohexylmethyl- (3-methyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -amide	346	480.21	481.2
347	330.24	331.2		348	344.26	345.3	1-methyl-1H-imidazole-4-carboxylic acid cyclohexylmethyl- (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -amide
349	426.14	427.1	2-chloro-N- (3-methyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -N- (1-methyl-1H-imidazol-4-ylmethyl) -3-trifluoromethyl-benzamide	348	344.26	345.3
349	426.14	427.1		350	434.19	435.1	6, 7-dihydro-5H-pyrrolo [1, 2-a ]]Imidazole-2-carboxylic acid (3-methyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	351	372.17	373.2	3-chloro-N- (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -N- (1-methyl-1H-imidazol-4-ylmethyl) -benzamide
352	468.19	469.28	1-propyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of	351	372.17	373.2
352	468.19	469.28		353	586.16	587.21	1- (4-trifluoromethoxy-phenyl) -1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]-amides of
354	468.19	469.27	1-isopropyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0]Hex-6-ylMethyl radical]-amides of	353	586.16	587.21
354	468.19	469.27		355	560.22	561.33	1- [2- (4-trifluoromethoxy-phenyl) -ethyl]-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-propyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -amide
356	414.22	415.3	1-propyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-propyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -amide	355	560.22	561.33
356	414.22	415.3		357	516.19	517.31	1- (4-trifluoromethyl-phenyl) -1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-propyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -amide
358	428.23	429.35	1-butyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-propyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -amide	357	516.19	517.31
358	428.23	429.35		359	546.2	547.33	1- (4-trifluoromethoxy-benzyl) -1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-propyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -amide
360	532.19	533.34	1- (4-trifluoromethoxy-phenyl) -1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-propyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -amide	359	546.2	547.33
360	532.19	533.34		361	414.22	415.33	1-isopropyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-propyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -amide
362	414.22	415.33	1-butyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -amide	361	414.22	415.33
362	414.22	415.33		363	468.15	469.27	1- (3-chloro-phenyl) -1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -amide
364	400.2	401.31	1-propyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -amide	363	468.15	469.27

Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name
Examples	MWCalc	Mass Spectrometry data (M +1)	IUPAC name	365	400.2	401.31	1-isopropyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -amide
366	518.17	519.29	1- (4-trifluoromethoxy-phenyl) -1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-ethyl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) -amide	365	400.2	401.31
366	518.17	519.29		367	472.18	473.1	1-methyl-1H-imidazole-4-carboxylic acid (3-pyrazin-2-yl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide
368	510.2	511.2	1-methyl-1H-imidazole-4-carboxylic acid [3- (1H-benzimidazol-2-yl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide	367	472.18	473.1
368	510.2	511.2		369	463.22	464.2	1-methyl-1H-imidazole-4-carboxylic acid [3- (1-methyl-azetidin-3-yl) -3-aza-bicyclo [3.1.0]Hex-6-ylmethyl]- (3-trifluoromethoxy-benzyl) -amide
370	399.18	400.2	1-methyl-1H-imidazole-4-carboxylic acid (3-azetidin-3-yl-3-aza-bicyclo [ 3.1.0)]Hex-6-ylmethyl) - (3-chloro-benzyl) -amide	369	463.22	464.2
370	399.18	400.2		371	362.83	363.1	N- (3-chloro-4-fluorobenzyl) -N- ((3-methyl-3-aza-bicyclo [ 3.1.0)]Hex-6-yl) methyl) -1H-imidazole-4-carboxamide

Melting points were measured with a Buchi micro melting point apparatus without calibration. The infrared absorption spectrum (IR) was measured with a Shimazu infrared spectrometer (IR-470). Unless otherwise specified, in CDCl₃Medium use Varian NMR spectrometer (Unity, 400MHz for¹H, 100MHz for¹³C) Measurement of¹H and¹³c nuclear magnetic resonance spectroscopy (NMR), peak position expressed as parts per million (ppm) shift from tetramethylsilane to low magnetic field (δ). The peak shape is represented as follows: s, singlet; d, double peak; t, triplet; m, multiplet; br, broad peak.

The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be included within the scope of the present invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

Claims

1. A compound of formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof,

formula I

Wherein R is₁Represents a heteroaryl group selected from: imidazolyl, thiazolyl, pyridyl, oxazolyl, pyrazolyl, triazolyl, oxadiazolyl, quinolinyl, isoxazolyl(ii) oxazolyl, pyrroloimidazolyl, and thiadiazole, wherein said heteroaryl is optionally substituted with one or more substituents selected from the group consisting of: -OH, -NR₇R₈Halogen, (C)₁-C₈) Alkyl, (C)₃-C₁₀) Cycloalkyl group, (C)₁-C₈) Alkoxy group, (C)₁-C₁₂) Alkoxyalkyl group, (C)₁-C₈) Hydroxyalkyl radical, (C)₆-C₁₄) Aryl and benzyl;

R₂、R₃and A independently represents H or (C)₁-C₈) Alkyl, wherein said alkyl is optionally substituted with one or more-OH, (C)₁-C₈) Alkoxy, -NR₇R₈Or halogen substitution;

R₆represents H, (C)₆-C₁₄) Aryl group, (C)₁-C₁₀) Alkyl, (C)₃-C₁₀) Cycloalkyl group, (C)₅-C₁₈) Bicycloalkyl, (C)₅-C₁₈) Tricycloalkyl, (3-10 membered) heterocycloalkyl, (5-10 membered) heteroaryl, -C (═ O) NR₇R₈OR-C (═ O) OR₇Wherein said R is₆Groups may be optionally substituted with one or more X groups;

2. The compound of claim 1, wherein stereochemistry is defined as formula II or formula III:

formula II formula III.

3. The compound of claim 1, wherein Z is (C)₆-C₁₄) Aryl, and R₄Or R₅Each independently is H, halogen, -CF₃、-OCF₃、(C₆-C₁₄) Aryl or (C)₆-C₁₄) An aryloxy group.

4. The compound of claim 1, wherein R₂、R₃And A is hydrogen.

5. The compound of claim 1, wherein Y is (C)₁-C₆) Alkyl, (C)₃-C₆) Cycloalkyl, (3-6 membered) heterocycloalkyl or-CH₂-(C₃-C₆) A cycloalkyl group; wherein Y is optionally substituted by halogen, OH, -SO₂R₁₀、-C(＝O)R₁₀or-CH₂CH₂CF₃And (4) substitution.

6. A compound according to claim 3, wherein R₁Is an imidazolyl group.

7. A compound having the formula:

q represents- (CH)₂)_n-, whereinn is 1, 2, 3 or 4, or- (CH)₂)_m-O-, wherein m is 2, 3 or 4;

R₆represents H, (C)₆-C₁₄) Aryl group, (C)₁-C₁₀) Alkyl, (C)₃-C₁₀) Cycloalkyl group, (C)₅-C₁₈) Bicycloalkyl, (C)₅-C₁₈) Tricycloalkyl, (3-10 membered) heterocycloalkyl, (5-10 membered) heteroaryl, -C (═ O) NR₇R₈OR-C (═ O) OR₇Wherein said R is₆Optionally substituted with one or more X groups;

8. The compound of claim 7, wherein Z is (C)₆-C₁₄) Aryl, and R₄Or R₅Each independently is H, halogen, -CF₃、-OCF₃、(C₆-C₁₄) Aryl or (C)₆-C₁₄) An aryloxy group.

9. The compound of claim 7, wherein R₂、R₃And A is hydrogen.

10. The compound of claim 7, wherein Y is (C)₁-C₆) Alkyl, (C)₃-C₆) Cycloalkyl, (3-20 membered) heterocycloalkyl or-CH₂-(C₃-C₆) A cycloalkyl group; wherein Y is optionally substituted by halogen, OH, -SO₂R₁₀、-C(＝O)R₁₀or-CH₂CH₂CF₃And (4) substitution.

11. The compound according to claim 1, wherein said compound is selected from the group consisting of:

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide hydrochloride;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethyl-benzyl) -amide hydrochloride;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-chloro-benzyl) -amide hydrochloride;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (4-fluoro-3-trifluoromethyl-benzyl) -amide hydrochloride;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-chloro-4-fluoro-benzyl) -amide hydrochloride;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (4-fluoro-3-isopropoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-cyclopentyloxy-4-fluoro-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - [3- (2, 2-dimethyl-propoxy) -4-fluoro-benzyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-cyclohexyloxy-4-fluoro-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - [3- (2, 2, 2-trifluoro-1-trifluoromethyl-ethyl) -benzyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - [3- (2, 2, 2-trifluoro-ethyl) -benzyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopropylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopentylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (4-trifluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-cyclopropylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-cyclopentylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (4-trifluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopropylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethyl-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (4-fluoro-3-trifluoromethyl-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - (3-methyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide hydrochloride;

1-methyl-1H-imidazole-4-carboxylic acid (3-methyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethyl-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-methyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethyl-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3, 5-dichloro-benzyl) - (3-methyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3, 5-dichloro-benzyl) - (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide hydrochloride;

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-4-fluoro-benzyl) - (3-methyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-4-fluoro-benzyl) - (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-methyl-3-aza-bicyclo [3.i.0] hex-6-ylmethyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-azetidin-3-yl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (2, 4-dichloro-benzyl) - (3-methyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (2, 4-dichloro-benzyl) - (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3, 4-dichloro-benzyl) - (3-methyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3, 4-dichloro-benzyl) - (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-methanesulfonyl-azetidin-3-yl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-azetidin-3-yl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (4-fluoro-3-trifluoromethyl-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-azetidin-3-yl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-chloro-4-fluoro-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - [3- (1-methyl-azetidin-3-yl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-4-fluoro-benzyl) - [3- (1-methyl-azetidin-3-yl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-azetidin-3-yl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethyl-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-methyl-azetidin-3-yl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethyl-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (1-methyl-azetidin-3-yl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-methyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - [3- (2, 2, 2-trifluoro-ethyl) -benzyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-methyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - [3- (2, 2, 2-trifluoro-1-trifluoromethyl-ethyl) -benzyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-hydroxy-cyclohexylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (2-chloro-phenyl) -2-hydroxy-ethyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-hydroxy-cyclopentylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3, 4-dichloro-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (2-trifluoromethyl-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-fluoro-5-trifluoromethyl-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethyl-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (2, 3-dichloro-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (2, 4-dichloro-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (2-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (4-fluoro-3-trifluoromethyl-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (2-fluoro-5-trifluoromethyl-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-phenyl-propyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (4-phenoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -biphenyl-4-ylmethyl-amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (4-phenyl-butyl) -amide;

pyridine-2-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -biphenyl-3-ylmethyl-amide;

pyridine-2-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (4-fluoro-3-trifluoromethyl-benzyl) -amide;

pyridine-2-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (5-fluoro-2-trifluoromethyl-benzyl) -amide;

thiazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethyl-benzyl) -amide;

pyridine-2-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (2-fluoro-5-trifluoromethyl-benzyl) -amide;

pyridine-2-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-fluoro-5-trifluoromethyl-benzyl) -amide;

thiazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (2-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (2-trifluoromethyl-benzyl) -amide;

thiazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - [2- (4-chloro-phenyl) -ethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - [2- (3-trifluoromethyl-phenyl) -ethyl ] -amide;

thiazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (2, 4-difluoro-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - [2- (3-chloro-phenyl) -ethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-isobutyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2, 2-dimethyl-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (tetrahydro-furan-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1H-imidazol-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-methyl-butyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (3H-imidazol-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (3-methyl-butyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-ethyl-butyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-isoxazol-3-ylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-methyl-pentyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-methyl-1H-pyrazol-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-ethyl-3-methyl-butyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-cyclohexylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-methyl-1H-pyrrol-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (3, 3-dimethyl-butyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (4-methyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-heptyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-methyl-1H-imidazol-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-methyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-bicyclo [2.2.1] hept-5-en-2-ylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (5-methyl-3H-imidazol-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2, 4-dimethyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (3-methyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1, 5-dimethyl-1H-pyrazol-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (4-cyano-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

2-methyl-3- (6- { [ (1-methyl-1H-imidazole-4-carbonyl) - (3-trifluoromethoxy-benzyl) -amino ] -methyl } -3-aza-bicyclo [3.1.0] hex-3-yl) -propionic acid ethyl ester;

1-methyl-1H-imidazole-4-carboxylic acid (3-phenethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-ethyl-3H-imidazol-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (4-ethyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (6-oxo-1, 6-dihydro-pyridin-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2, 5-dimethyl-2H-pyrazol-3-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-p-tolyl-ethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-ethyl-5-methyl-3H-imidazol-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (4-methoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-ethyl-hexyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-ethyl-3-methyl-1H-pyrazol-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (5-methoxymethyl-furan-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (3-phenyl-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (3-fluoro-4-methyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (4-chloro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-ethyl-5-methyl-1H-pyrazol-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2, 5-difluoro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (4-chloro-1-methyl-1H-pyrazol-3-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-chloro-pyridin-3-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1H-benzoimidazol-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (3, 5-difluoro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1H-indol-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-chloro-thiazol-5-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2, 3-difluoro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1H-indol-5-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (3, 5, 5-trimethyl-hexyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2, 4-difluoro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (4-isopropyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-benzo [1, 3] dioxol-5-ylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-pyridin-2-yl-1H-pyrrol-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-naphthalen-2-ylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-benzo [1, 3] dioxol-4-ylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-pyrimidin-2-yl-1H-pyrrol-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-naphthalen-1-ylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [3- (5-methyl-furan-2-yl) -butyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (6, 6-dimethyl-bicyclo [3.1.1] hept-2-en-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-benzothiazol-2-ylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (4-difluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (4-trifluoromethyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-biphenyl-4-ylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (3-trifluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (3-phenyl-butyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (6-phenoxy-pyridin-3-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (4-phenoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (2-trifluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (4-fluoro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopropylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (4-fluoro-3-trifluoromethyl-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopentylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (4-fluoro-3-trifluoromethyl-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - [3- (4-trifluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - [3- (1-hydroxy-cyclohexylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - [3- (4-phenoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

thiazole-4-carboxylic acid (3-phenethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-cyclopropylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-cyclopentylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (4-chloro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (4-fluoro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3- { [ ethyl- (2-hydroxy-ethyl) -carbamoyl ] -methyl } -3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (sec-butyl-methyl-carbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (1-methyl-1H-pyrazol-3-ylcarbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole 4-carboxylic acid (3-cyclopropylcarbamoylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1H-imidazole-4-carboxylic acid (3-cyclopropylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (cyclopropylmethyl-carbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (tert-butylcarbamoyl-methyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-cyclobutylcarbamoylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (2-methoxy-ethylcarbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (2-methoxy-1-methyl-ethylcarbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopentylcarbamoylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (2-hydroxy-propylcarbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-phenylcarbamoylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (1H-imidazol-2-ylcarbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (isopropylcarbamoyl-methyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (2, 2-dimethyl-propylcarbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (pyridin-3-ylcarbamoylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3- { [ methyl- (3-methyl-pyridin-2-ylmethyl) -carbamoyl ] -methyl } -3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (2-hydroxy-1, 1-dimethyl-ethylcarbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (pyridin-2-ylcarbamoylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (2-methyl-2H-pyrazol-3-ylcarbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (2, 2, 2-trifluoro-ethylcarbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3- { [ (furan-2-ylmethyl) -carbamoyl ] -methyl } -3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-dimethylcarbamoylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (1-methyl-1H- [1, 2, 4] triazol-3-ylcarbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-cyclohexylcarbamoylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-oxo-2-pyrrolidin-1-yl-ethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (2-methyl-pyrrolidin-1-yl) -2-oxo-ethyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-oxo-2-piperidin-1-yl-ethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (cyclopropylmethyl-methyl-carbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-morpholin-4-yl-2-oxo-ethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (3-hydroxy-pyrrolidin-1-yl) -2-oxo-ethyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (ethyl-isopropyl-carbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (carbamoylmethyl-methyl-carbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (3-methyl-piperidin-1-yl) -2-oxo-ethyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (4-methyl-piperidin-1-yl) -2-oxo-ethyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- (2-oxo-2-thiazolidin-3-yl-ethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (3-hydroxymethyl-pyrrolidin-1-yl) -2-oxo-ethyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (2-hydroxymethyl-pyrrolidin-1-yl) -2-oxo-ethyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (3-hydroxy-piperidin-1-yl) -2-oxo-ethyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-oxo-2-thiomorpholin-4-yl-ethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (2, 6-dimethyl-morpholin-4-yl) -2-oxo-ethyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (methyl-thiophen-2-ylmethyl-carbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (furan-2-ylmethyl-methyl-carbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (benzyl-methyl-carbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (1, 3-dihydro-isoindol-2-yl) -2-oxo-ethyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [2- (3, 4-difluoro-pyrrolidin-1-yl) -2-oxo-ethyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3- { [ methyl- (2, 2, 2-trifluoro-ethyl) -carbamoyl ] -methyl } -3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (methyl-thiophen-3-ylmethyl-carbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ (methyl-phenethyl-carbamoyl) -methyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3- { [ methyl- (1-pyridin-4-yl-ethyl) -carbamoyl ] -methyl } -3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ 2-oxo-2- (3-phenyl-pyrrolidin-1-yl) -ethyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3- { [ (2-methanesulfonyl-ethyl) -methyl-carbamoyl ] -methyl } -3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid {3- [ 2-oxo-2- (2-pyridin-4-yl-pyrrolidin-1-yl) -ethyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - [3- (2-hydroxy-indan-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - [3- (6-phenoxy-pyridin-3-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

thiazole-4-carboxylic acid [3- (3-methyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (2-fluoro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (4-methoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-cyclohexylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (3-fluoro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (2-methyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (4-phenoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (2-phenyl-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (4-cyano-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-biphenyl-4-ylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (3-cyano-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (4-trifluoromethyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

thiazole-4-carboxylic acid [3- (3, 5-dimethyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (3-chloro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (2, 4-dimethyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (3-trifluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

thiazole-4-carboxylic acid [3- (4-ethyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (4-trifluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

thiazole-4-carboxylic acid [3- (1-methyl-1H-imidazol-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (5-methoxymethyl-furan-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (6-oxo-1, 6-dihydro-pyridin-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (1-ethyl-3-methyl-1H-pyrazol-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (1-methyl-1H-pyrrol-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (2-trifluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

thiazole-4-carboxylic acid (3-furan-3-ylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (1, 5-dimethyl-1H-pyrazol-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (1H-imidazol-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (1H-pyrrol-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (3-phenyl-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (1-methyl-1H-pyrazol-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (4-fluoro-3-methyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (5-methyl-3H-imidazol-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-furan-2-ylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

(6- { [ (thiazole-4-carbonyl) - (3-trifluoromethoxy-benzyl) -amino ] -methyl } -3-aza-bicyclo [3.1.0] hex-3-yl) -acetic acid butyl ester;

thiazole-4-carboxylic acid [3- (3-fluoro-4-methyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (2-ethyl-3H-imidazol-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (2-ethyl-5-methyl-3H-imidazol-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (tetrahydro-furan-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (2-p-tolyl-ethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (1-ethyl-5-methyl-1H-pyrazol-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (2-chloro-pyridin-3-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-isoxazol-3-ylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (1H-indol-3-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

2-methyl-3- (6- { [ (thiazole-4-carbonyl) - (3-trifluoromethoxy-benzyl) -amino ] -methyl } -3-aza-bicyclo [3.1.0] hex-3-yl) -propionic acid ethyl ester;

thiazole-4-carboxylic acid [3- (5-methyl-2H-pyrazol-3-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (4-butoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-benzo [1, 3] dioxol-5-ylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (4-ethoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (4-isopropyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (4-methyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-naphthalen-2-ylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-benzo [1, 3] dioxol-4-ylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (2, 3-difluoro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (2, 5-difluoro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-quinolin-7-ylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (4-methoxy-3-methyl-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (2, 4-difluoro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid {3- [3- (5-methyl-furan-2-yl) -butyl ] -3-aza-bicyclo [3.1.0] hex-6-ylmethyl } - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (1-pyrimidin-2-yl-1H-pyrrol-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (3, 5-difluoro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (4-difluoromethoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-quinolin-8-ylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (2-butyl-1H-imidazol-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (1H-indol-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (3-cyano-4-fluoro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (1H-indol-5-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (2-fluoro-4-methoxy-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (1H-benzoimidazol-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (2-chloro-thiazol-5-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid [3- (4-chloro-1-methyl-1H-pyrazol-3-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-hydroxy-indan-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (1-hydroxy-cyclohexylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (2-hydroxy-indan-2-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-hydroxy-cyclohexylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethyl-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-hydroxy-cyclopentylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethyl-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopentylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethyl-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid cyclohexylmethyl- (3-cyclopropylmethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-hydroxy-2-methyl-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-trifluoromethoxy-benzyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopentyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-cyclobutyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (4-chloro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -cyclohexylmethyl-amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (2-hydroxy-cyclopentyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1, 5-dimethyl-1H-pyrazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

5-methyl-isoxazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

4, 5-dichloro-isothiazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

5-propyl-isoxazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (4-fluoro-3-isopropoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-cyclopentyloxy-4-fluoro-benzyl) -amide;

thiazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - [3- (2, 2-dimethyl-propoxy) -4-fluoro-benzyl ] -amide;

thiazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-cyclohexyloxy-4-fluoro-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3, 5-dichloro-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-isopropyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

quinoline-2-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

pyridine-2-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

5-ethyl-isoxazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

quinine-4-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

5-cyclopropyl-2H-pyrazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

2-ethyl-5-methyl-2H-pyrazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

4-methyl-1H-imidazole-2-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

5-isopropyl-2H-pyrazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-pyrazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

5-ethyl-2-methyl-2H-pyrazole-3-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

2-isopropyl-thiazole-4-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

thiazole-4-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

5-chloro-pyridine-2-carboxylic acid (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid pentyl- [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (2-methyl-butyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (2-ethyl-butyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid cyclopropylmethyl- [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid heptyl- [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid butyl- [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid cyclohexylmethyl- [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (4-chloro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (2-methyl-butyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-cyclopentyl-propyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (4-chloro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -pentyl-amide;

1-methyl-1H-imidazole-4-carboxylic acid butyl- [3- (4-chloro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (4-chloro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -cyclopropylmethyl-amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (4-chloro-benzyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (2-ethyl-butyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (tetrahydro-pyran-4-yl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (4-hydroxy-tetrahydro-pyran-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (4-hydroxy-tetrahydro-pyran-4-ylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (tetrahydro-pyran-4-yl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (4-fluoro-3-trifluoromethyl-benzyl) - [3- (tetrahydro-pyran-4-yl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-methyl-1H-imidazole-4-carboxylic acid cyclohexylmethyl- (3-methyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid cyclohexylmethyl- (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

2-chloro-N- (3-methyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -N- (1-methyl-1H-imidazol-4-ylmethyl) -3-trifluoromethyl-benzamide;

6, 7-dihydro-5H-pyrrolo [1, 2-a ] imidazole-2-carboxylic acid (3-methyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

3-chloro-N- (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -N- (1-methyl-1H-imidazol-4-ylmethyl) -benzamide;

1-propyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1- (4-trifluoromethoxy-phenyl) -1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1-isopropyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - [3- (3, 3, 3-trifluoro-propyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] -amide;

1- [2- (4-trifluoromethoxy-phenyl) -ethyl ] -1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-propyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-propyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-propyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1- (4-trifluoromethyl-phenyl) -1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-propyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-butyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-propyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1- (4-trifluoromethoxy-benzyl) -1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-propyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1- (4-trifluoromethoxy-phenyl) -1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-propyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-isopropyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-propyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-butyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1- (3-chloro-phenyl) -1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-propyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-isopropyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1- (4-trifluoromethoxy-phenyl) -1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-ethyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-pyrazin-2-yl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1H-benzoimidazol-2-yl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-methyl-azetidin-3-yl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid (3-azetidin-3-yl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) - (3-chloro-benzyl) -amide;

n- (3-chloro-4-fluorobenzyl) -N- ((3-methyl-3-aza-bicyclo [3.1.0] hex-6-yl) methyl) -1H-imidazole-4-carboxamide.

12. The compound according to claim 7, wherein said compound is selected from the group consisting of:

1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-benzyl) - (3-methyl-3-aza-bicyclo [3.1.0] hex-6-ylmethyl) -amide;

1-methyl-1H-imidazole-4-carboxylic acid [3- (1-hydroxy-cyclopentylmethyl) -3-aza-bicyclo [3.1.0] hex-6-ylmethyl ] - (3-trifluoromethoxy-benzyl) -amide.

13. A pharmaceutical composition for treating a disorder or condition selected from the group consisting of: psychosis, schizophrenia, conduct disorder, disruptive behavior disorder, bipolar disorder, psychotic episodes of anxiety, anxiety and psychosis co-morbidities, psychotic affective disorder; behavioral manifestations of mental retardation, conduct disorder and autism; dyskinesia and Tourette's syndrome co-morbid, akinesia-strauss syndrome, dyskinesia and parkinson's disease co-morbid, tardive dyskinesia and other drug induced and neurodegenerative based dyskinesias; attention deficit hyperactivity disorder; cognitive and memory disorders comprising an amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof effective to treat these dysfunctions or conditions.

14. A pharmaceutical composition for the treatment of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other dysfunctions in a mammal comprising a compound of formula I according to claim 1 and at least one antipsychotic agent selected from the group consisting of: ziprasidone (Geodon), clozapine, molindone, loxapine, pimozide, risperidone, olanzapine, remopride, sertindole, amisulpride, quetiapine, prochlorperazine, fluphenazine, trifluoperazine, thioridazine, haloperidol, chlorpromazine, flupentixol and pipothiazine.

15. A method of treatment of a dysfunction or condition selected from psychosis, schizophrenia, conduct disorder, disruptive behavior disorder, bipolar disorder, psychotic episodes of anxiety, anxiety and psychotic co-morbidities, psychotic affective disorder, in a mammal, including a human; behavioral manifestations of mental retardation, conduct disorder and autism; dyskinesia and Tourette's syndrome co-morbid, akinesia-strauss syndrome, dyskinesia and parkinson's disease co-morbid, tardive dyskinesia and other drug induced and neurodegenerative based dyskinesias; attention deficit hyperactivity disorder; cognitive and memory disorders comprising administering to a mammal in need of such treatment a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof in an amount effective to treat such conditions or disorders.

16. A method of treatment of a dysfunction or condition selected from psychosis, schizophrenia, conduct disorder, disruptive behavior disorder, bipolar disorder, psychotic episodes of anxiety, anxiety and psychotic co-morbidities, psychotic affective disorder, in a mammal, including a human; behavioral manifestations of mental retardation, conduct disorder and autism; dyskinesia and Tourette's syndrome co-morbid, akinesia-strauss syndrome, dyskinesia and parkinson's disease co-morbid, tardive dyskinesia and other drug induced and neurodegenerative based dyskinesias; attention deficit hyperactivity disorder; cognitive and memory disorders comprising administering to a mammal in need of such treatment an amount of a compound of formula I according to claim 1 and at least one antipsychotic agent selected from: ziprasidone (Geodon), clozapine, molindone, loxapine, pimozide, risperidone, olanzapine, remopride, sertindole, amisulpride, quetiapine, prochlorperazine, fluphenazine, trifluoperazine, thioridazine, haloperidol, chlorpromazine, flupentixol and pipothiazine.